粘附分子检测在脑梗死诊断和治疗中的应用
|
摘要
目的评价粘附分子检测在脑梗死临床诊断和治疗中的价值。方法流式细胞仪和酶联免疫吸附法测定颈动脉粥样硬化(CAS)和脑梗死患者外周血白细胞﹑血小板粘附分子的表达,血小板-白细胞凝集性,血清可溶性粘附分子的浓度。免疫组化和原位杂交检测大鼠缺血/再灌注模型内皮细胞粘附分子的表达。结果血小板膜糖蛋白在CAS患者中的表达升高,是CAS发生的独立危险因素;伴脑梗死CAS患者较不伴脑梗死者白细胞﹑血小板粘附分子表达升高,血清可溶性粘附分子浓度增高,血小板-白细胞凝集性增加,粘附分子是CAS患者出现脑梗死的独立危险因素;可溶性细胞间粘附分子-1(sICAM-1)是非栓塞性脑梗死复发的独立危险因素;巴曲酶和通心络治疗涉及到粘附分子。结论粘附分子可作为CAS和脑梗死发病的预测指标和药物治疗的监测指标。
Objective To evaluate the value of detection adhesion molecules for the diagnosis and treatment of cerebral infarction. Methods By flow cytometry and enzyme-lined immunosorbent assay,the expression of adhesion molecule on leukocyte﹑platelets,platelet-leukocyte aggregates and the concentrations of soluble adhesion molecule from peripheral blood were measured in patients with carotid atherosclerosis(CAS)and cerebral infarction. The expression of adhesion molecule on endothelial cell were detected by immunohistochemistry and in situ hybridization in rat cerebral ischemia/reperfusion models. Results The expression of platelet membrance glycoprotein was increased in patients with CAS and it was an independent risk factor in CAS.The expression of adhesion mocules on leukocyte﹑platelets,platelet-leukocyte aggregates and the concentrations of soluble forms were elevated in CAS with infarction patients compared to without infarction.Adhesion molecule was an independent risk factor in CAS occurring cerebral infarction.Soluble intercellular adhesion molecule-1(sICAM-1) was a independent risk factors in nonembolic ischemic stroke recurrent.The treatment of bartroxobin and Tong Xin Luo involved in adhesion molecules.Conclusions Adhesion molecules may as a index of predict and treatment monitoring for cerebral infarction.
Objective To evaluate the value of detection adhesion molecules for the diagnosis and treatment of cerebral infarction. Methods By flow cytometry and enzyme-lined immunosorbent assay,the expression of adhesion molecule on leukocyte﹑platelets,platelet-leukocyte aggregates and the concentrations of soluble adhesion molecule from peripheral blood were measured in patients with carotid atherosclerosis(CAS)and cerebral infarction. The expression of adhesion molecule on endothelial cell were detected by immunohistochemistry and in situ hybridization in rat cerebral ischemia/reperfusion models. Results The expression of platelet membrance glycoprotein was increased in patients with CAS and it was an independent risk factor in CAS.The expression of adhesion mocules on leukocyte﹑platelets,platelet-leukocyte aggregates and the concentrations of soluble forms were elevated in CAS with infarction patients compared to without infarction.Adhesion molecule was an independent risk factor in CAS occurring cerebral infarction.Soluble intercellular adhesion molecule-1(sICAM-1) was a independent risk factors in nonembolic ischemic stroke recurrent.The treatment of bartroxobin and Tong Xin Luo involved in adhesion molecules.Conclusions Adhesion molecules may as a index of predict and treatment monitoring for cerebral infarction.
引文
1. Sachais BS.Platelet-endothelial interactions in atherosclerosis.Curr Atheroscler Rep,2001,3(5):412-6.
2. 黄铮,龚兰生,施仲伟,等.冠心病患者颈动脉粥样硬化斑块的好发部位及超声分型.中国超声医学杂志,1996,12(5):34-7.
3. 王 建 中 , 孙 市 , 王 淑 娟 , 等 . 流 式 细 胞 术 检 测 活 化 血 小 板 . 中 华 医 学 检 验 杂志,1994,17(4):232-5.
4. Rinder HM,Bonan JL,Rinder CS,et al.Activated and unactivated platelet adhesion to monocytes and neutrophils.Blood,1991,78(7):1760-9.
5. Ott I,Neumann FJ,Gawaz M et al.Increased neutrophil platelet adhesion in patients with unstable angina.Circulation,1996,94(6):1239-44.
6. Mickelson JK,Lakkis NM,Villarreal-Levy G,et al.Leukocyte activation with platelet adhesion after coronary angioplasty:a mechanism for recurrent disease? J Am Coll Cardiol,1996,28(2):345-53.
7. Chakhtoura EY,Shamoon FE,Haft JI,et al.Comparison of platelet activation in unstable and stable angina pectoris and correlation with coronary angiographic findings.Am J Cardiol,2000,86(8):835-9.
8. Ramsis N,El-Hawary AA,Ismail E.Relation between carotid intima-media thickness, platelet surface activation and endothelial cell markers.Haemostasis,1998, 28(5):268-75.
9. Furman MI,Benoit SE,Barnard MR,et al.Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease.J Am Coll Cardiol,1998,31(2):352-8.
10. Michelson AD,Barnard MR,Krueger LA,et al.Evaluation of platelet function by flow cytometry.Methods,2000,21(3):259-70.
11. Nadar SK,Blann AD,Kamath S,et al.Platelet indexes in relation to target organdamage in high-risk hypertensive patients: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT).J Am Coll Cardiol,2004,44(2):415-22..
12. Holme PA,Orvim U,Hamers MJ,et al.Shear-induced platelet activation and platelet microparticle formation at blood flow conditions as in arteries with a severe stenosis. Arterioscler Thromb Vasc Biol,1997,17(4):646-53.
13. Kawano H,Tsuji H,Nishimura H,et al.Serotonin induces the expression of tissue factor and plasminogen activator inhibitor-1 in cultured rat aortic endothelial cells. Blood 2001,97(6):1697-702.
14. Gawaz M, Brand K, Dickfeld T, et al. Platelets induce alterations of chemotactic and adhesive properties of endothelial cells mediated through an interleukin-1 -dependent mechanism.Atherosclerosis,2000,48(1):75-85.
15. Yip HK,Chen SS,Liu JS,et al.Serial changes in platelet activation in patients after ischemic stroke:role of pharmacodynamic modulation.Stroke,2004,35(7): 1683-7.
16. Wallaschofski H,Lohmann T,Hild E,et al.Enhanced platelet activation by prolactin in patients with ischemic stroke.Thromb Haemost,2006,96(1):38-44.
1. Golledge J,Greenhalgh RM,Davies AH.The symptomatic carotid plaque.Stroke, 2000,31(3):774-81.
2. Schumacher H,Kaiser E,Schnabel PA,et al.Immunophenotypic characterisation of carotid plaque:increased amount of inflammatory cells as an independent predictor for ischaemic symptoms.Eur J Vasc Endovasc Surg,2001,21(6):494-501.
3. 中华神经科学会 中华神经外科学会.各类脑血管疾病诊断要点.中华神经科杂志,1996,29(6):379-80.
4. 黄铮,龚兰生,施仲伟,等.冠心病患者颈动脉粥样硬化斑块的好发部位及超声分型.中国超声医学杂志,1996,12(5):34-7.
5. Schillinger M,Exner M,Mlekusch W,et al.Inflammation and Carotid Artery--Risk for Atherosclerosis Study (ICARAS).Circulation,2005,111(17):2203-9.
6. Kiechl S,Egger G,Mayr M,et al.Chronic infections and the risk of carotid atherosclerosis: prospective results from a large population study.Circulation, 2001,103(8):1064-70.
7. Elkind MS,Cheng J,Boden-Albala B,et al.Elevated white blood cell count and carotid plaque thickness:the northern manhattan stroke study.Stroke,2001, 32(4):842-9.
8. Hashimoto H,Kitagawa K,Kuwabara K,et al.Circulating adhesion molecules are correlated with ultrasonic assessment of carotid plaques.Clin Sci (Lond),2003, 104(5):521-7.
9. Rohde LE,Lee RT,Rivero J,et al.Circulating cell adhesion molecules are correlated with ultrasound-based assessment of carotid atherosclerosis. Arterioscler Thromb Vasc Biol,1998,18(11):1765-70.
10. Kondo K,Kitagawa K,Nagai Y,et al.Associations of soluble intercellular adhesion molecule-1 with carotid atherosclerosis progression.Atherosclerosis,2005, 179(1):155-60.
11. McCabe DJ,Harrison P,Mackie IJ, et al.Increased platelet count and leucocyte-platelet complex formation in acute symptomatic compared with asymptomatic severe carotid stenosis.J Neurol Neurosurg Psychiatry,2005,76(9): 1249-54.
12. Shoji T,Koyama H,Fukumoto S,et al.Platelet-monocyte aggregates are independently associated with occurrence of carotid plaques in type 2 diabeticpatients.J Atheroscler Thromb,2005,12(6):344-52.
13. Galante A, Pietroiusti A, Magrini A, et al.Leucocyte rheological properties are altered in patients with diffuse atherosclerosis.Thromb Haemost,1997, 77(6):1073-6.
14. Blankenberg S,Barbaux S,Tiret L.Adhesion molecules and atherosclerosis. Atherosclerosis.2003,170(2):191-203.
15. Mocco J,Choudhri TF,Mack WJ,et al.Elevation of soluble intercellular adhesion molecule-1 levels in symptomatic and asymptomatic carotid atherosclerosis. Neurosurgery,2001,48(4):718-21.
16. Glowinska B,Urban M,Peczynska J,et al.Soluble adhesion molecules (sICAM-1, sVCAM-1) and selectins (sE selectin, sP selectin, sL selectin) levels in children and adolescents with obesity,hypertension,and diabetes.Metabolism, 2005,54(8):1020-6.
17. Blankenberg S,Barbaux S,Tiret L.Adhesion molecules and atherosclerosis. Atherosclerosis.2003,170(2):191-203.
18. Oguchi S,Dimayuga P,Zhu J,et al.Monoclonal antibody against vascular cell adhesion molecule-1 inhibits neointimal formation after periadventitial carotid artery injury in genetically hypercholesterolemic mice.Arterioscler Thromb Vasc Biol,2000,20(7):1729-36.
19. Htun P,Fateh-Moghadam S,Tomandl B,et al.Course of platelet activation and platelet-leukocyte interaction in cerebrovascular ischemia.Stroke,2006,37(9): 2283-7.
20. Kurabayashi H,Tamura J,Naruse T,et al.Possible existence of platelet activation before the onset of cerebral infarction.Atherosclerosis,2000,153(1):203-7.
21. Furman MI,Benoit SE,Barnard MR,et al.Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease.J Am Coll Cardiol,1998,31(2):352-8.
22. Yang PY, Almofti MR, Lu L,et al.Reduction of atherosclerosis in cholesterol-fed rabbits and decrease of expressions of intracellular adhesion molecule-1 and vascular endothelial growth factor in foam cells by a water-soluble fractionof Polygonum multiflorum.J Pharmacol Sci,2005,99(3):294-300.
23. Barnett HJ, Meldrum HE.Endarterectomy for carotid stenosis:new approaches in patient selection.Cerebrovasc Dis,2001,11 (Suppl 1):105-11.
1 Petty GW,Brown RD Jr,Whisnant JP,et al.Survival and recurrence after first cerebral infarction:a population-based study in Rochester,Minnesota,1975 through 1989.Neurology,1998,50(1):208-16.
2 Malik I,Danesh J,Whincup P,et al.Soluble adhesion molecules and prediction of coronary heart disease:a prospective study and meta-analysis.Lancet,2001, 358(9286):971–5.
3 Tanne D,Haim M,Boyko V,et al.Soluble intercellular adhesion molecule-1 and risk of future ischaemic stroke: a nested case-control study from the Bezafibrate Infarction Prevention (BIP) study cohort.Stroke,2002,33(9):2182–6.
4 Kawamura T,Umemura T,Kanai A, et al.Soluble adhesion molecules and C-reactive protein in the progression of silent cerebral infarction in patients with type
2 diabetes mellitus.Metabolism,2006,55(4):461-6.
5 Jenny NS, Arnold AM, Kuller LH, et al.Soluble intracellular adhesion molecule-1 is associated with cardiovascular disease risk and mortality in older adults. J Thromb Haemost.2006,4(1):107-13.
6 中华神经科学会 中华神经外科学会.各类脑血管疾病诊断要点.中华神经科杂志,1996,29(6):379-380.
7 夏斌,邵福源,赵忠新,等.急性缺血性脑血管病患者血清可溶性黏附分子的变化.上海医学,2002,25(5):308-9.
8 Sheinart KF,Tuhrim S,Horowitz DR,et al.Stroke recurrence is more frequent in Blacks and Hispanics.Neuroepidemiology,1998,17(4):188-98.
9 Appelros P,Nydevik I,Viitanen M.Poor outcome after first-ever stroke:predictors for death,dependency,and recurrent stroke within the first year.Stroke, 2003,34(1):122-6.
10 Blankenberg S,Barbaux S,Tiret L.Adhesion molecules and atherosclerosis. Atherosclerosis,2003,170(2):191-203.
11 Preston RA,Ledford M,Materson BJ,et al.Effects of severe, uncontrolled hypertension on endothelial activation:soluble vascular cell adhesion molecule-1, soluble intercellular adhesion molecule-1 and von Willebrand factor.J Hypertens,2002,20(5):871-7.
12 Takeuchi N,Kawamura T,Kanai A,et al.The effect of cigarette smoking on soluble adhesion molecules in middle-aged patients with Type 2 diabetes mellitus.Diabet Med,2002,19(1):57-64.
13 Romano M,Mezzetti A,Marulli C,et al.Fluvastatin reduces soluble P-selectin and ICAM-1 levels in hypercholesterolemic patients: role of nitric oxide.J Investig Med,2000,48(3):183-9.
14 Libby P,Ridker PM,Maseri A.Inflammation and atherosclerosis.Circulation,2002, 105(9):1135-43.
15 Golledge J,Greenhalgh RM,Davies AH.The symptomatic carotid plaque.Stroke, 2000,31(3):774-81.
16 DeGraba TJ,Siren AL,Penix L,et al.Increased endothelial expression of intercellular adhesion molecule-1 in symptomatic versus asymptomatic human carotid atherosclerotic plaque.Stroke.1998,29(7):1405–10.
17 Mocco J,Choudhri TF,Mack WJ,et al.Elevation of soluble intercellular adhesion molecule-1 levels in symptomatic and asymptomatic carotid atherosclerosis. Neurosurgery,2001,48(4):718-21.
18 Nawawi H,Osman NS,Annuar R,et al.Soluble intercellular adhesion molecule-1 and interleukin-6 levels reflect endothelial dysfunction in patients with primaryhypercholesterolaemia treated with atorvastatin.Atherosclerosis,2003,169(2): 283-91.
19 Kowalski J,Okopien B,Madej A,et al.Effects of fenofibrate and simvastatin on plasma sICAM-1 and MCP-1 concentrations in patients with hyperlipoproteinemia. Int J Clin Pharmacol Ther,2003,41(6):241-7.
1. 夏斌,张玲珍,邵福源,等.缺血性卒中患者白细胞CD11b和CD18表达的动态观察.中风与神经疾病杂志,2000,17(2):85-7.
2. 夏斌,张玲珍,邵福源,等.缺血性卒中患者白细胞粘附分子的表达.中国神经精神疾病杂,2000,26(5):310-1.
3. Xia Bin,Shao Fuyuan,Zhao Zhongxin.Dynamic observation of the levels of sICAM-1 and sVCAM-1 in the patients with acute ischemic stroke. 中国临床 神经科学,2000,8(增刊):73.
4. 夏斌,张玲珍,邵福源,等.急性缺血性脑卒中患者血小板膜糖蛋白的表达.中华老年医学杂志,1999,18(6):337-9.
5. 夏斌,张玲珍,邵福源,等.缺血性卒中患者血小板-白细胞粘附性的变化.中华老年医学杂志,2000,19(3):223-4.
6. 中华神经科学会 中华神经外科学会.各类脑血管疾病诊断要点.中华神经科杂志,1996,29(6):379-80.
7. 陈清棠,赵玉宾,郑亚文,等.巴曲酶注射液治疗急性脑梗死的临床实验.中风与神经疾病杂志,2000,17(1):27-30.
8. Xu G,Liu X,Zhu W,et al.Feasibility of treating hyperfibrinogenemia with intermittently administered batroxobin in patients with ischemic stroke/transient ischemic attack for secondary prevention.Blood Coagul Fibrinolysis,2007,18(2):193-7.
9. Wu W,Kuang P,Jiang S,et al.Effects of batroxobin on spatial learning and memory disorder of rats with temporal ischemia and the expression of HSP32 and HSP70. J Tradit Chin Med,2000,20(4):297-301.
10. 苏志强,刘亢丁,饶明俐.不同剂量巴曲酶对大鼠局灶性脑缺血再灌流后细胞凋亡的影响.中风与神经疾病杂志.2001,18(1):12-3.
11. 潘钰, 丛琳,张朝东.巴曲酶治疗糖尿病大鼠局灶性脑缺血再灌注损伤的实验研究.中国康复理论与实践,2004,10 (9):526-8.
12. 李振光,伍期专,姚存姗.脑梗死小鼠凋亡神经元及脑血管内皮细胞超微结构的观察.中华老年心血管杂志,2000,2(2):128.
13. 郭志权,张泉静,张晓华.东菱克栓酶、尿激酶对沙土鼠脑缺血再灌注模型白细胞与内皮细胞粘附抑制的实验观察.山西医科大学学报,2000,31(3):199-201.
14. Kato H, Kogure K, Liu XH, et al. Progressive expression of immunomolecules on activated microglia and invading leukocytes following focal cerebral ischemia in the rat.Brain Res,1996,734(1-2):203-212.
15. Price CJ,Menon DK,Peters AM,et al.Cerebral Neutrophil Recruitment, Histology, and Outcome in Acute Ischemic Stroke.Stroke,2004,35(7):1659-64.
16. Zhang RL,Zhang ZG,Chopp M,et al. Thrombolysis with tissue plasminogen activator alters adhesion molecule expression in the ischemic rat brain.Stroke, 1999,30(3):624-9.
17. Michelson AD,Barnard MR,Krueger LA,et al.Evaluation of platelet function by flow cytometry.Methods,2000,21(3):259-70.
18. Kawano K,Aoki I,Aoki N,et al. Human platelet activation by thrombolytic agents:effects of tissue-type plasminogen activator and urokinase on platelet surface P-selectin expression.Am Heart J,1998,135:268-71.
19. Coulter SA,Cannon CP,Ault KA,et al.High levels of platelet inhibition with abciximab despite heightened platelet activation and aggregation during thrombolysis for acute myocardial infarction:results from TIMI (thrombolysis in myocardial infarction).Circulation,2000,101(23):2690-5.
20. 曹茂红,柯开富.巴曲酶联合抗血小板聚集药治疗急性脑梗死的疗效观察.临床神经病学杂志,2006,19(2):141-3.
1. Schumacher H,Kaiser E,Schnabel PA,et al.Immunophenotypic characterisation of carotid plaque:increased amount of inflammatory cells as an independent predictor for ischaemic symptoms.Eur J Vasc Endovasc Surg,2001,21(6):494-501.
2. 夏斌,赵忠新,方平,等.伴脑梗死颈动脉粥样硬化与血小板激活的关系.上海医学,2003,26(3):197-199.
3. 黄铮,龚兰生,施仲伟,等.冠心病患者颈动脉粥样硬化斑块的好发部位及超声分型.中国超声医学杂志,1996,12(5):34-37.
4. 夏斌,张玲珍,邵福源,等.急性缺血性脑卒中患者血小板膜糖蛋白的表达.中华老年医学杂志,1999,18(6):337-339.
5. 夏斌,张玲珍,邵福源,等.缺血性卒中患者血小板-白细胞粘附性的变化.中华老年医学杂志, 2000,19(3):223-223.
6. Furman MI,Benoit SE,Barnard MR,et al.Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease.J Am Coll Cardiol,1998,31(2):352-358.
7. Kaplar M,Kappelmayer J,Veszpremi A,et al.The possible association of in vivo leukocyte-platelet heterophilic aggregate formation and the development of diabetic angiopathy.Platelets,2001,12(7):419-422.
8. Golledge J,Greenhalgh RM,Davies AH.The symptomatic carotid plaque. Stroke,2000,31(3):774-781.
9. 史载祥,任在方,黄力,等.通心络胶囊对急性脑梗死患者血浆 D-D 聚体、plg、AT-Ⅲ含量的影响.浙江中西医结合杂志,2002,12:471-472.
10. Kawano H,Tsuji H,Nishimura H,et al.Serotonin induces the expression of tissue factor and plasminogen activator inhibitor-1 in cultured rat aortic endothelial cells.Blood 2001,97(6):1697-1702.
1. Frijns CJ,Kappelle LJ.Inflammatory cell adhesion molecules in ischemic cerebrovascular disease.Stroke,2002,33(8):2115-2122.
2. 董志领,邵汝生,李建华,等.通心络胶囊治疗脑梗塞临床观察.中国中医基础医学杂志,2001,7:(4):66-67.
3. Longa EZ,Weinstein PR,Carlson S,et al. Reversible middle cerebral artery occlusion without craniectomy in rats.Stroke,1989,20(1):84-91.
4. Ding Y,Li J,Rafols JA,et al.Prereperfusion saline infusion into ischemic territory reduces inflammatory injury after transient middle cerebral artery occlusion in rats.Stroke,2002,33(10):2492-2498.
5. Zhang RL,Chopp M,Zaloga C,,et al.The temporal profiles of ICAM-1 protein and mRNA expression after transient MCA occlusion in the rat.Brain Res,1995,682(1-2):182-188.
6. Justicia C,Martin A,Rojas S,et al.Anti-VCAM-1 antibodies did not protect against ischemic damage either in rats or in mice.J Cereb Blood Flow Metab,2006,26(3):421-432
7. 周东华,张莉莉,陈曼娥.脑缺血再灌注 ICAM-1 的表达与神经元损伤.第三军医大学学报,2000,22(2):115-118.
8. 王中孝,蔡竖平,徐洁.脑缺血/再灌注脑微血管内皮细胞 ELAM-1 和 ICAM-1mRNA 表达的研究.中国应用生理学杂志,2001,17(3):236-238.
9. 雷万龙,刘勇,袁群芳,等.大鼠局部脑缺血区 VCAM-1 表达和单核/巨噬细胞浸润的研究.中华微生物学和免疫学杂志,2000,20(2):105.
10. 周东华,邓娟,陈曼娥.通心络胶囊对脑缺血-再灌注大鼠保护作用的实验研究.中国急救医学.2001,21(8):435-437.
11. Furuya K,Takeda H,Azhar S,et al.Examination of several potential mechanisms for the negative outcome in a clinical stroke trial of enlimomab, a murine anti-human intercellular adhesion molecule-1 antibody: a bedside-to-bench study. Stroke,2001,32(11):2665-2674.
1. Huang J,Upadhyay UM,Tamargo RJ.Inflammation in stroke and focal cerebral ischemia.Surg Neurol,2006,66(3):232-45.
2. Gee JM,Kalil A,Shea C,et al.Lymphocytes:Potential Mediators of Postischemic Injury and Neuroprotection.Stroke,2007,38(2):783–8.
3. Frijns CJ,Kappelle LJ.Inflammatory cell adhesion molecules in ischemic cerebrovascular disease.Stroke,2002,33(8):2115–22.
4. Blankenberg S,Barbaux S,Tiret L.Adhesion molecules and atherosclerosis. Atherosclerosis.2003,170(2):191-203.
5. Quehenberger O.Thematic review series:the immune system and atherogenesis. Molecular mechanisms regulating monocyte recruitment in atherosclerosis.J Lipid Res,2005,46(8):1582-90.
6. Hafezi-Moghadam A,Thomas KL,Prorock AJ,et al.L-selectin shedding regulates leukocyte recruitment.J Exp Med,2001,193(7):863–72.
7. Leeuwenberg JF,Smeets EF,Neefjes JJ,et al.E-selectin and intercellular adhesion molecule-1 are released by activated human endothelial cells in vitro.Immunology,1992,77(4):543-9.
8. Ishiwata N,Takio K,Katayama M, et al. Alternatively spliced isoform of P-selectin is present in vivo as a soluble molecule.J Biol Chem,1994,269 (38):23708–15.
9. Berger G,Hartwell DW,Wagner DD.P-Selectin and platelet clearance.Blood,1998,92(11):4446-52.
10. Sako D,Chang XJ,Barone KM,et al.Expression cloning of a functionalalligand for P-selectin. Cell,1993,75(6):1179-86.
11. Norman KE,Katopodis AG,Thoma G,et al. P-selectin glycoprotein ligand-1 supports rolling on E- and P-selectin in vivo.Blood,2000,96(10): 3585–91.
12. Steegmaier M,Levinovitz A,Isenmann S, et al. The E-selectin-ligand ESL-1 is a variant of a receptor for fibroblast growth factor.Nature,1995,373 (6515): 615–20.
13. Kansas GS. Selectins and their ligands:current concepts and controversies. Blood,1996,88(9):3259–87.
14. Warnock RA,Askari S,Butcher EC,et al.Molecular mechanisms of lymphocyte homing to peripheral lymph nodes.J Exp Med,1998,187(2):205–16.
15. Leeuwenberg JF,Smeets EF,Neefjes JJ,et al.E-selectin and intercellular adhesion molecule-1 are released by activated human endothelial cells in vitro. Immunology,1992,77 (4):543–9.
16. del Pozo MA,Pulido R,Munoz C, et al. Regulation of ICAM-3 (CD50) membrane expression on human neutrophils through a proteolytic shedding mechanism. Eur. J. Immunol,1994,24(11):2586–94.
17. Champagne B,Tremblay P,Cantin A, et al. Proteolytic cleavage of ICAM-1 by human neutrophil elastase.J Immunol,1998,161(11):6398–405.
18. Fiore E,Fusco C,Romero P,et al.Matrix metalloproteinase 9 (MMP-9/gelatinase B) proteolytically cleaves ICAM-1 and participates in tumor cell resistance to natural killer cell-mediated cytotoxicity.Oncogene,2002,21(34):5213–23.
19. Matheny HE,Deem TL,Cook-Mills JM.Lymphocyte migration through monolayers of endothelial cell lines involves VCAM-1 signaling via endothelial cell NADPH oxidase.J Immunol,2000,164(12):6550–9.
20. Leca G,Mansur SE,Bensussan A.Expression of VCAM-1 (CD106) by a subset of TCR gamma delta-bearing lymphocyte clones.Involvement of a metalloprotase in the specific hydrolytic release of the soluble isoform.J Immunol,1995,154 (3): 1069–77.
21. Newton JP, Buckley CD,Jones EY,et al.Residues on both faces of the first immunoglobulin fold contribute to homophilic binding sites of PECAM-1/CD31. J Biol Chem,1997,272(33):20555–63.
22. Goldberger A, Middleton KA,Oliver JA,et al. Biosynthesis and processing of the cell adhesion molecule PECAM-1 includes production of a soluble form.J Biol Chem,1994,269(25):17183-91.
23. Hughes PE,Pfaff M.Integrin affinity modulation.Trends Cell Biol,1998,8(9): 359-64.
24. Lynam E, Sklar LA,Taylor AD,et al.Beta2-integrins mediate stable adhesion in collisional interactions between neutrophils and ICAM-1-expressing cells.J Leukocyte Biol,1998,64(5):622–30.
25. Lefer AM.Role of the beta2-integrins and immunoglobulin superfamily members in myocardial ischemia-reperfusion.Ann.Thorac Surg,1999,68(15):1920–3.
26. Rose DM,Grabovsky V,Alon R,et al.The affinity of integrin alpha(4)beta(1)governs lymphocyte migration.J Immunol,2001,167(5):2824–30.
27. Moiseeva EP. Adhesion receptors of vascular smooth muscle cells and their functions.Cardiovasc Res,2001,52(3):372–86.
28. Cines DB,Pollak ES, Buck CA,et al.Endothelial cells in physiology and in the pathophysiology of vascular disorders.Blood,1998,91(10):3527–61.
29. Somers WS,Tang J, Shaw GD, et al.Insights into the molecular basis of leukocyte tethering and rolling revealed by structures of P- and E-selectin bound to SLe(X) and PSGL-1.Cell,2000,103(3):467–79.
30. Ohmori K,Kanda K,Mitsuoka C,et al.P- and E-selectins recognize sialyl 6-sulfo Lewis X,the recently identified L-selectin ligand.Biochem Biophys Res Commun, 2000,278(1):90–6.
31. Carlos TM, Harlan JM.Leukocyte-endothelial adhesion molecules. Blood, 1994,84(7): 2068–101.
32. Clark WM, Zivin JA.Antileukocyte adhesion therapy:preclinical trials and combination therapy.Neurology,1997,49(suppl 4):S32–S38.
33. Jean WC,Spellman SR,Nussbaum ES,et al.Reperfusion injury after focal cerebral ischemia:the role of inflammation and the therapeutic horizon. Neurosurgery, 1998,43(6):1382–96.
34. Matsuo Y,Onodera H,Shiga Y,et al.Correlation between myeloperoxidase -quantified neutrophil accumulation and ischemic brain injury in the rat: effects of neutrophil depletion.Stroke,1994,25(7):1469–75.
35. Kochanek PM,Hallenbeck JM.Polymorphonuclear leukocytes and monocytes /macrophages in the pathogenesis of cerebral ischemia and stroke.Stroke, 1992,23(9):1367–79.
36. Mori E,del Zoppo GJ,Chambers JD,et al. Inhibition of polymorphonuclear leukocyte adherence suppresses no-reflow after focal cerebral ischemia in baboons.Stroke,1992,23(5):712–8.
37. Dutka AJ,Kochanek PM,Hallenbeck JM.Influence of granulocytopenia on canine cerebral ischemia induced by air embolism.Stroke,1989,20(3):390–5.
38. Hallenbeck JM,Dutka AJ,Tanishima T,et al. Polymorphonuclear leukocyte accumulation in brain regions with low blood flow during the early postischemic period.Stroke,1986,17(2):246–53.
39. Prentice RL,Szatrowski TP, Kato H,et al.Leukocyte counts and cerebrovascular disease.J Chron Dis,1982,35 (9):703–14.
40. Bednar MM,Gross CE,Balazy M,et al.Antineutrophil strategies. Neurology,1997,49 (suppl 4):S20–S22.
41. Pozzilli C,Lenzi GL Argentino C,et al.Imaging of leukocytic infiltration in human cerebral infarcts.Stroke,1985,16(2):251–5.
42. Emerich DF, Dean RL,Bartus RT.The role of leukocytes following cerebral ischemia: pathogenic variable or bystander reaction to emerging infarct? Exp Neurol,2002,173(1): 168–81.
43. Barone FC, Feuerstein GZ.Inflammatory mediators and stroke:new opportunities for novel therapeutics.J Cereb Blood Flow Metab,1999,9(8):819–34.
44. Clark WM. Cytokines and reperfusion injury.Neurology,1997, 49 (suppl 4): S10–S14.
45. Kuroda S, Siesjo BK.Reperfusion damage following focal ischemia: pathophysiology and therapeutic windows.Clin Neurosci,1997,4(4):199–212.
46. Zhang RL,Chopp M,Chen H,et al.Temporal profile of ischemic tissue damage, neutrophil response,and vascular plugging following permanent and transient (2H) middle cerebral artery occlusion in the rat.J Neurol Sci,1994,125(1):3–10.
47. van Lookeren C,Thomas GR,Thibodeaux H,et al.Secondary reduction in the apparent diffusion coefficient of water,increase in cerebral blood volume,and delayed neuronal death after middle cerebral artery occlusion and early reperfusion in the rat.J Cereb Blood Flow Metab,1999,19(12):1354–64.
48. Zhang RL,Zhang ZG,Chopp M,et al.Thrombolysis with tissue plasminogen activator alters adhesion molecule expression in the ischemic rat brain.Stroke, 1999,30(3):624–9.
49. Zhang RL,Zhang ZG,Chopp M.Increased therapeutic efficacy with rt-PA and anti-CD18 antibody treatment of stroke in the rat.Neurology,1999, 52(2):273–9.
50. Kidwell CS,Saver JL,Mattiello J,et al.Thrombolytic reversal of acute human cerebral ischemic injury shown by diffusion/perfusion magnetic resonance imaging.Ann Neurol,2000,47(4):462–9.
51. Price CJ,Menon DK,Peters AM,et al.Cerebral Neutrophil Recruitment, Histology, and Outcome in Acute Ischemic Stroke.Stroke,2004,35(7):1659-64.
52. Okada Y,Copeland BR,Mori E,et al.P-selectin and intercellular adhesion molecule-1 expression after focal brain ischemia and reperfusion.Stroke, 1994,25(1):202–11.
53. Jander S,Kraemer M,Schroeter M,et al.Lymphocytic infiltration and expression of intercellular adhesion molecule-1 in photochemically induced ischemia of the rat cortex.J Cereb Blood Flow Metab,1995,15(1):42–51.
54. Zhang RL,Chopp M,Zaloga C,et al.The temporal profiles of ICAM-1 protein and mRNA expression after transient MCA occlusion in the rat.Brain Res,1995, 682(1-2):182–8.
55. Wang X,Yue TL,Barone FC,et al.Demonstration of increased endothelial-leukocyte adhesion molecule-1 mRNA expression in rat ischemic cortex.Stroke, 1995,26(9):1665–8.
56. Haring HP,Berg EL,Tsurushita N,et al.E-selectin appears in nonischemic tissue during experimental focal cerebral ischemia.Stroke,1996,27(8):1386–91.
57. Zhang RL,Chopp M,Zhang ZG,et al.E-selectin in focal cerebral ischemia and reperfusion in the rat.J Cereb Blood Flow Metab,1996,16(6):1126–36.
58. Huang J,Choudhri TF,Winfree CJ,et al.Postischemic cerebrovascular E-selectin expression mediates tissue injury in murine stroke.Stroke,2000,31(12): 3047–53.
59. Zhang R,Chopp M,Zhang Z,et al.The expression of P- and E-selectins in three models of middle cerebral artery occlusion.Brain Res,1998, 785(2):207–14.
60. Suzuki H,Abe K,Tojo S,et al.Expressions of P-selectin- and HSP72-like immunoreactivities in rat brain after transient middle cerebral artery occlusion.Brain Res,1997,759(2):321–9.
61. Suzuki H,Abe K,Tojo S,et al.A change of P-selectin immunoreactivity in rat brain after transient and permanent middle cerebral artery occlusion.Neurol Res,1998,20(5):463–9.
62. Hess DC,Zhao W,Carroll J,et al.Increased expression of ICAM-1 during reoxygenation in brain endothelial cells.Stroke,1994,25(7):1463–7.
63. Stanimirovic DB,Wong J,Shapiro A,et al.Increase in surface expression of ICAM-1,VCAM-1 and E-selectin in human cerebromicrovascular endothelial cells subjected to ischemia-like insults.Acta Neurochir Suppl (Wien),1997,70:12–6.
64. Howard EF,Chen Q,Cheng C,et al.NF-kappa B is activated and ICAM-1 gene expression is upregulated during reoxygenation of human brain endothelial cells.Neurosci Lett,1998,248(3):199–203.
65. Soriano SG,Coxon A,Wang YF,et al.Mice deficient in Mac-1 (CD11b/CD18) are less susceptible to cerebral ischemia/reperfusion injury.Stroke,1999,30(1):134–9.
66. Kitagawa K,Matsumoto M,Mabuchi T,et al.Deficiency of intercellular adhesion molecule-1 attenuates microcirculatory disturbance and infarction size in focal cerebral ischemia.J Cereb Blood Flow Metab,1998,18(12):1336–45.
67. Connolly ES Jr,Winfree CJ,Springer TA,et al.Cerebral protection in homozygous null ICAM-1 mice after middle cerebral artery occlusion: role of neutrophil adhesion in the pathogenesis of stroke.J Clin Invest,1996,97(1):209–16.
68. Suzuki H,Abe K,Tojo SJ,et al.Reduction of ischemic brain injury by anti- P-selectin monoclonal antibody after permanent middle cerebral artery occlusion in rat.Neurol Res,1999,21(3):269-76.
69. Zhang ZG, Chopp M, Tang WX, et al.Postischemic treatment (2-4 h) with anti-CD11b and anti-CD18 monoclonal antibodies are neuroprotective after transient (2 h) focal cerebral ischemia in the rat.Brain Res,1995,698(1-2):79-85.
70. Zhang RL,Chopp M, Li Y,et al.Anti-ICAM-1 antibody reduces ischemic cell damage after transient middle cerebral artery occlusion in the rat.Neurology, 1994,44(9):1747-51.
71. Chopp M, Zhang RL,Chen H,et al.Postischemic administration of an anti-Mac-1 antibody reduces ischemic cell damage after transient middle cerebral artery occlusion in rats.Stroke,1994,25(4):869-75.
72. Clark WM,Madden KP,Rothlein R,et al.Reduction of central nervous system ischemic injury by monoclonal antibody to intercellular adhesion molecule.J Neurosurg,1991,75(4):623–27.
73. Matsuo Y,Onodera H,Shiga Y,et al.Role of cell adhesion molecules in brain injury after transient middle cerebral artery occlusion in the rat.Brain Res,1994,656(2):344–52.
74. Bowes MP, Zivin JA, Rothlein R.Monoclonal antibody to the ICAM-1 adhesion site reduces neurological damage in a rabbit cerebral embolism stroke model.Exp Neurol,1993,119(2):215–9.
75. Chen H,Chopp M,Zhang RL,et al.Anti-CD11b monoclonal antibody reduces ischemic cell damage after transient focal cerebral ischemia in rat.Ann Neurol,1994, 35(4):458–63.
76. Chopp M,Zhang RL,Jiang N.The role of adhesion molecules in reducing cerebralischemic cell damage.Adv Neurol,1996,71: 315–26.
77. Zhang RL,Chopp M,Jiang N,et al.Anti-intercellular adhesion molecule-1 antibody reduces ischemic cell damage after transient but not permanent middle cerebral artery occlusion in the Wistar rat.Stroke,1995,26(8):1438–42.
78. Chopp M,Li Y,Jiang N,et al.Antibodies against adhesion molecules reduce apoptosis after transient middle cerebral artery occlusion in rat brain.J Cereb Blood Flow Metab,1996,16(4):578–84.
79. Morikawa E,Zhang SM,Seko Y,et al.Treatment of focal cerebral ischemia with synthetic oligopeptide corresponding to lectin domain of selectin.Stroke, 1996,27(5):951–5.
80. Goussev AV,Zhang Z,Anderson DC,et al.P-selectin antibody reduces hemorrhage and infarct volume resulting from MCA occlusion in the rat.J Neurol Sci,1998, 161(1):16-22.
81. Relton JK,Sloan KE,Frew EM,et al.Inhibition of 4 integrin protects against transient focal cerebral ischemia in normotensive and hypertensive rats.Stroke, 2001,32(1):199–205.
82. Becker K,Kindrick D,Relton J,et al.Antibody to the 4 integrin decreases infarct size in transient focal cerebral ischemia in rats.Stroke,2001,32(1): 206–11.
83. Bowes MP,Rothlein R,Fagan SC,et al.Monoclonal antibodies preventing leukocyte activation reduce experimental neurologic injury and enhance efficacy of thrombolytic therapy.Neurology,1995,45(4):815–9.
84. Bednar MM,Gross CE,Russell SR,et al.Humanized anti-L-selectin monoclonal antibody DREG200 therapy in acute thromboembolic stroke.Neurol Res,1998, 20(5):403–8.
85. Justicia C,Martin A,Rojas S,et al.Anti-VCAM-1 antibodies did not protect against ischemic damage either in rats or in mice.J Cereb Blood Flow Metab, 2006,26(3):421-432.
86. Enlimomab Acute Stroke Trial Investigators.Use of anti-ICAM-1 therapy in ischemic stroke: results of the Enlimomab Acute Stroke Trial.Neurology,2001, 57(8):1428–34.
87. Kanemoto Y,Nakase H,Akita N,et al.Effects of anti-intercellular adhesion molecule-1 antibody on reperfusion injury induced by late reperfusion in the rat middle cerebral artery occlusion model.Neurosurgery,2002,51(4):1034-41.
88. Mocco J,Choudhri T,Huang J,et al.HuEP5C7 as a humanized monoclonal anti-E/ P-selectin neurovascular protective strategy in a blinded placebo-controlled trial of nonhuman primate stroke.Circ Res,2002,91(10):907-14.
89. Lehmberg J,Beck J,Baethmann A,et al.Effect of P-selectin inhibition on leukocyte-endothelium interaction and survival after global cerebral ischemia. J Neurol,2006,253(3):357-63.
90. Atkinson C,Zhu H,Qiao F,et al.Complement-dependent P-selectin expression and injury following ischemic stroke.J Immunol,2006,177(10):7266-74.
91. Vemuganti R,Dempsey RJ,Bowen KK,et al.Inhibition of intercellular adhesion molecule-1 protein expression by antisense oligonucleotides is neuroprotectiveafter transient middle cerebral artery occlusion in rat.Stroke,2004,35(1): 179-84.
92. Zhang L,Zhang ZG,Zhang R,et al.Adjuvant treatment with a glycoprotein IIb/IIIa receptor inhibitor increases the therapeutic window for low-dose tissue plasminogen activator administration in a rat model of embolic strok. Circulation,2003,107(22):2837-43.
93. Ding G, Jiang Q,Zhang L,et al.Analysis of combined treatment of embolic stroke in rat with r-tPA and a GPIIb/IIIa inhibitor.J Cereb Blood Flow Metab,2005, 25(1):87-97.
94. Zhang L,Zhang ZG,Zhang C,et al.Intravenous administration of a GPIIb/IIIa receptor antagonist extends the therapeutic window of intra-arterial tenecteplase-tissue plasminogen activator in a rat stroke model.Stroke, 2004,35(12):2890-5.
95. Qureshi AI,Suri MF,Ali Z,et al.Intraarterial reteplase and intravenous abciximab for treatment of acute ischemic stroke.A preliminary feasibility and safety study in a non-human primate model.Neuroradiology,2005,47(11):845-54.
96. Moriguchi A, Mihara K,Aoki T,et al.Restoration of middle cerebral artery thrombosis by novel glycoprotein IIb/IIIa antagonist FK419 in guinea pig.Eur J Pharmacol,2004,498(1-3):179-88.
97. Maeda M,Moriguchi A,Mihara K,et al.FK419,a nonpeptide platelet glycoprotein IIb/IIIa antagonist,ameliorates brain infarction associated with thrombotic focal cerebral ischemia in monkeys:comparison with tissue plasminogen activator.J Cereb Blood Flow Metab,2005,25(1):108-18.
98. Lapchak PA,Araujo DM,Song D,et al. The nonpeptide glycoprotein IIb/IIIa platelet receptor antagonist SM-20302 reduces tissue plasminogen activator- induced intracerebral hemorrhage after thromboembolic stroke.Stroke,2002, 33(1):147-52.
99. Hu H,Zhang W,Li N.Glycoprotein IIb/IIIa inhibition attenuates platelet- activating factor-induced platelet activation by reducing protein kinase C activity.J Thromb Haemost,2003,1(8):1805-12.
100.Ritter LS,Stempel KM,Coull BM,et al.Leukocyte-platelet aggregates in rat peripheral blood after ischemic stroke and reperfusion.Biol Res Nurs,2005,6(4):281-8.
101. Zhang L,Zhang ZG,Zhang RL,et al.Effects of a selective CD11b/CD18 antagonist and recombinant human tissue plasminogen activator treatment alone and in combination in a rat embolic model of stroke.Stroke,2003,34(7):1790-5.
102. Carloni S,Mazzoni E,Cimino M,et al.Simvastatin reduces caspase-3 activation and inflammatory markers induced by hypoxia-ischemia in the newborn rat.Neurobiol Dis,2006,21(1):119-26.
103.Miao H,Jiang L,Huang L.Effects of simvastatin on the expression of intercellular adhesion molecule-1 mRNA in neonatal brain with hypoxic-ischemic damage.J Nanosci Nanotechnol,2005,5(8):1261-5.
104.Zhang L,Zhang ZG,Ding GL,et al.Multitargeted effects of statin-enhanced thrombolytic therapy for stroke with recombinant human tissue-type plasminogenactivator in the rat.Circulation,2005,112(22):3486-94.
105. Furuichi Y,Noto T,Li JY,et al.Multiple modes of action of tacrolimus (FK506) for neuroprotective action on ischemic damage after transient focal cerebral ischemia in rats.Brain Res,2004,1014(1-2):120-30.
106. Noto T,Furuichi Y,Ishiye M,et al.Tacrolimus (FK506) Limits Accumulation of Granulocytes and Platelets and Protects against Brain Damage after Transient Focal Cerebral Ischemia in Rat.Biol Pharm Bull,2007,30(2):313-7.
107. Khan M,Jatana M,Elango C,et al.Cerebrovascular protection by various nitric oxide donors in rats after experimental stroke.Nitric Oxide,2006,15(2):114-24.
108. Williams AJ, Dave JR,Tortella FC.Neuroprotection with the proteasome inhibitor MLN519 in focal ischemic brain injury:relation to nuclear factor kappaB (NF-kappaB),inflammatory gene expression, and leukocyte infiltration. Neurochem Int,2006,49(2):106-12.
109.He W,Xu XJ.Attenuation of brain inflammatory response after focal cerebral ischemia/reperfusion with Xuesaitong injection in rats.Chin J Integr Med,2006,12(3):203-6.
110. Cheng Y,Zhang HT,Sun L,et al.Involvement of cell adhesion molecules in polydatin protection of brain tissues from ischemia-reperfusion injury.Brain Res,2006, 1110(1):193-200.
111. Hu XM,Zhang Y,Zeng FD.Effects of sodium beta-aescin on expression of adhesion molecules and migration of neutrophils after middle cerebral artery occlusion in rats.Acta Pharmacol Sin,2004,25(7):869-75.
112.Wang YH,Wang WY,Chang CC,et al.Taxifolin ameliorates cerebral ischemia- reperfusion injury in rats through its anti-oxidative effect and modulation of NF-kappa B activation.J Biomed Sci,2006,13(1):127-41.
113.Littleton-Kearney MT,Gaines JM,Callahan KP,et al.Effects of estrogen on platelet reactivity after transient forebrain ischemia in rats.Biol Res Nurs, 2005,7(2):135-45.
114. Bowen KK,Naylor M,Vemuganti R.Prevention of inflammation is a mechanism of preconditioning-induced neuroprotection against focal cerebral ischemia. Neurochem Int,2006,49(2):127-35.
115. Duan H,Cheng L,Sun X,et al.LFA-1 and VLA-4 involved in human high proliferative potential-endothelial progenitor cells homing to ischemic tissue.Thromb Haemost,2006,96(6):807-15.
116. Zhang J,Rui YC,Yang PY,et al.C-reactive protein induced expression of adhesion molecules in cultured cerebral microvascular endothelial cells.Life Sci,2006, 78(26):2983-8.
117. Rassoul F,Salvetter J,Reissig D,et al.The influence of garlic (Allium sativum) extract on interleukin 1alpha-induced expression of endothelial intercellular adhesion molecule-1 and vascular cell adhesion molecule-1.Phytomedicine, 2006,13(4):230-5.
118. Handrigan MT,Burns AR,Donnachie EM,et al.Hydroxyethyl starch inhibits neutrophil adhesion and transendothelial migration.Shock,2005,24(5):434-9.
119.Wang GJ,Deng HY,Maier CM,et al.Mild hypothermia reduces ICAM-1 expression, neutrophil infiltration and microglia/monocyte accumulation following experimental stroke.Neuroscience,2002,114(4):1081–90.
120.Arumugam TV,Salter JW,Chidlow JH,et al.Contributions of LFA-1 and Mac-1 to brain injury and microvascular dysfunction induced by transient middle cerebral artery occlusion.Am J Physiol Heart Circ Physiol,2004,287(6):H2555-60.
121.Chen Y,Ruetzler C,Pandipati S,et al.Mucosal tolerance to E-selectin provides cell-mediated protection against ischemic brain injury.Proc Natl Acad Sci U S A.2003,100(25):15107-12.
122.Kim JS,Chopp M,Chen H,et al.Adhesive glycoproteins CD11a and CD18 are upregulated in the leukocytes from patients with ischemic stroke and transient ischemic attacks.J Neurol Sci,1995,128(1):45–50.
123.Fiszer U,Korczak-Kowalska G,Palasik W,et al.Increased expression of adhesion molecule CD18 (LFA-1beta) on the leukocytes of peripheral blood in patients with acute ischemic stroke.Acta Neurol Scand,1998, 97(4):221–224.
124.夏斌,邵福源,赵忠新,等.急性缺血性脑血管病患者血清可溶性黏附分子的变化.上海医学,2002,25(5):308-9.
125.夏斌,张玲珍,邵福源,等.缺血性脑血管意外患者白细胞 CD11b 和 CD18 的表达.中华内科杂志,1999,38(9):637-8.
126.夏斌,张玲珍,邵福源,等.缺血性卒中患者白细胞粘附分子的表达.中国神经精神疾病杂志,2000,26(5):310-1.
127.夏斌,张玲珍,邵福源,等.急性缺血性脑卒中患者血小板膜糖蛋白的表达.中华老年医学杂志,1999,18(6):337-9.
128.夏斌,张玲珍,邵福源,等.缺血性卒中患者血小板-白细胞粘附性的变化.中华老年医学杂志,2000,19(3):223-4.
129.Sanchez-Moreno C,Dashe JF,Scott T,et al.Decreased levels of plasma vitamin C and increased concentrations of inflammatory and oxidative stress markers after stroke.Stroke,2004,35(1):163-8.
130. Simundic AM,Basic V,Topic E,et al.Soluble adhesion molecules in acute ischemic stroke.Clin Invest Med,2004,27(2):86-92.
131. Licata G,Tuttolomondo A,Corrao S,et al.Immunoinflammatory activation during the acute phase of lacunar and non-lacunar ischemic stroke:association with time of onset and diabetic state.Int J Immunopathol Pharmacol,2006,19(3):639-46.
132. Castellanos M, Castillo J, Garcia MM,et al.Inflammation-mediated damage in progressing lacunar infarctions:a potential therapeutic target.Stroke,2002, 33(4):982-7.
133. Wang JY,Zhou DH,Li J,et al.Association of soluble intercellular adhesion molecule 1 with neurological deterioration of ischemic stroke:The Chongqing Stroke Study.Cerebrovasc Dis,2006,21(1-2):67-73.
134.Wang J,Li J,Liu Q.Association between platelet activation and fibrinolysis in acute stroke patients.Neurosci Lett,2005,384(3):305-9.
135. Cherian P,Hankey GJ, Eikelboom JW,et al.Endothelial and platelet activation in acute ischemic stroke and its etiological subtypes.Stroke,2003,34(9):2132-7.
136.Kozuka K,Kohriyama T,Nomura E,et al.Endothelial markers and adhesion molecules in acute ischemic stroke--sequential change and differences in stroke subtype. Atherosclerosis.2002,161(1):161-8.
137. Brondani R,Rieder CR,Valente D,et al.Levels of vascular cell adhesion molecule-1 and endothelin-1 in ischemic stroke: A longitudinal prospective study.Clin Biochem,2007,40(3-4):282-4.
138.Rodriguez-Yanez M,Castellanos M,Blanco M,et al.New-onset hypertension and inflammatory response/poor outcome in acute ischemic stroke.Neurology,2006, 67(11):1973-8.
139.Nadar SK,Lip GY,Blann AD.Platelet morphology, soluble P selectin and platelet P-selectin in acute ischaemic stroke. The West Birmingham Stroke Project.Thromb Haemost,2004,92(6):1342-8.
140.Htun P, Fateh-Moghadam S,Tomandl B,et al.Course of platelet activation and platelet-leukocyte interaction in cerebrovascular ischemia.Stroke,2006,37(9): 2283-7.
141.Anzej S,Bozic M,Antovic A, et al.Evidence of hypercoagulability and inflammation in young patients long after acute cerebral ischaemia.Thromb Res. 2006,[Epub ahead of print]
142.McCabe DJ,Harrison P,Mackie IJ,et al.Platelet degranulation and monocyte-platelet complex formation are increased in the acute and convalescent phases after ischaemic stroke or transient ischaemic attack.Br J Haematol, 2004,125(6):777-87.
143.Marquardt L, Ruf A, Mansmann U,et al. Course of Platelet Activation Markers After Ischemic Stroke.Stroke,2002,33(11):2570-4.
144. Wang J,Li J,Liu Q.Association between platelet activation and fibrinolysis in acute stroke patients.Neurosci Lett,2005,384(3):305-9.
145. Li N, Hu H, Hjemdahl P.Aspirin treatment does not attenuate platelet or leukocyte activation as monitored by whole blood flow cytometry.Thromb Res.2003, 111(3):165-70.
146. Serebruany VL,Malinin AI,Oshrine BR,et al.Lack of uniform platelet activation in patients after ischemic stroke and choice of antiplatelet therapy.Thromb Res, 2004,113(3-4):197-204.
147. Serebruany VL,Malinin AI,Ziai W,et al.Effects of clopidogrel and aspirin in combination versus aspirin alone on platelet activation and major receptor expression in patients after recent ischemic stroke:for the Plavix Use for Treatment of Stroke (PLUTO-Stroke) trial.Stroke,2005,36(10):2289-92.
148. Yip HK,Chen SS,Liu JS,et al.Serial changes in platelet activation in patients after ischemic stroke:role of pharmacodynamic modulation.Stroke,2004, 35(7):1683-7.
149. Wallaschofski H, Lohmann T, Hild E,et al.Enhanced platelet activation by prolactin in patients with ischemic stroke.Thromb Haemost,2006,96(1):38-44.
150.Tomiyasu H,Ishikawa K,Yamamoto M,et al.Effect of anticholesterol therapy on soluble ICAM-1 in chronic stroke patients with hyperlipidemia.Tokai J Exp ClinMed,2005,30(1):63-9.
151.Cha JK,Jeong MH,Kim JW.Statin reduces the platelet P-selectin expression in atherosclerotic ischemic stroke.J Thromb Thrombolysis,2004,18(1):39-42.
152. Zeller JA,Lenz A,Eschenfelder CC,et al.Platelet-leukocyte interaction and platelet activation in acute stroke with and without preceding infection. Arterioscler Thromb Vasc Biol,2005,25(7):1519-23.
153.Sobel RA,Mitchell ME,Fondren G.Intercellular adhesion molecule-1 (ICAM-1) in cellular immune reactions in the human central nervous system.Am J Pathol,1990,136(6):1309–16.
154.Krupinski J,Kaluza J,Kumar P,et al.Role of angiogenesis in patients with cerebral ischemic stroke.Stroke,1994,25(9):1794–8.
155.Lindsberg PJ,Carpen O,Paetau A,et al.Endothelial ICAM-1 expression associated with inflammatory cell response in human ischemic stroke. Circulation,1996, 94(5):939–5.
156. Padma V, Fisher M, Moonis M.et al.Thrombolytic therapy for acute ischemic stroke: 3 h and beyond.Expert Rev Neurother,2005,5(2):223-33.
157. Kaneider NC,Leger AJ,Kuliopulos A.Therapeutic targeting of molecules involved in leukocyte-endothelial cell interactions.FEBS J, 2006,273(19): 4416-24.
158.DeGraba TJ.The role of inflammation after acute stroke:utility of pursuing anti-adhesion molecule therapy.Neurology,1998,51(suppl 3):S62–8.
159.Schneider D,Berrouschot J,Brandt T,et al.Safety, pharmacokinetics and biological activity of enlimomab (anti-ICAM-1 antibody):an open-label,dose escalation study in patients hospitalized for acute stroke.Eur Neurol,1998, 40(2):78–83.
160.Vuorte J,Lindsberg PJ,Kaste M,et al.Anti-ICAM-1 monoclonal antibody R6.5 (enlimomab) promotes activation of neutrophils in whole blood.J Immunol,1999, 162(4):2353–7.
161.Furuya K,Takeda H,Azhar S,et al.Examination of several potential mechanisms for the negative outcome in a clinical stroke trial of enlimomab,a murine anti-human intercellular adhesion molecule-1 antibody: a bedside-to-bench study.Stroke, 2001,32(11):2665–74.
162.del Zoppo GJ,Hallenbeck JM.Advances in the vascular pathophysiology of ischemic stroke.Thromb Res,2000,98(3): 73–81.
163.Zanette EM,Roberti C,Mancini G,et al.Spontaneous middle cerebral artery reperfusion in ischemic stroke:a follow-up study with transcranial Doppler. Stroke,1995,26(3):430–3.
164.Lu M,Krams M,Zhang L,et al.Assessing combination treatments in acute stroke: preclinical experiences.Behav Brain Res,2005,162(2):165-72.
165. Mileski WJ,Burkhart D,Hunt JL,et al.Clinical effects of inhibiting leukocyte adhesion with monoclonal antibody to intercellular adhesion molecule-1 (enlimomab) in the treatment of partial-thickness burn injury.J Trauma, 2003,54(5):950-8.
166. Salmela K,Wramner L,Ekberg H,et al.A randomized multicenter trial of theanti-ICAM-1 monoclonal antibody (enlimomab) for the prevention of acute rejection and delayed onset of graft function in cadaveric renal transplantation: a report of the European Anti-ICAM-1 Renal Transplant Study Group. Transplantation,1999,67(5):729-36.
167.Jiang N,Chopp M,Chahwala S.Neutrophil inhibitory factor treatment of focal cerebral ischemia in the rat.Brain Res,1998,788(1-2):25–34.
168.Lees KR,Diener HC,Asplund K,et al;UK-279,276-301 Study Investigators. UK-279,276,a neutrophil inhibitory glycoprotein,in acute stroke:tolerability and pharmacokinetics.Stroke,2003,34(7):1704–9.
169.Krams M, Lees KR, Hacke W,et al. ASTIN Study Investigators. Acute Stroke Therapy by Inhibition of Neutrophils (ASTIN):an adaptive dose-response study of UK-279,276 in acute ischemic stroke.Stroke,2003,34(11):2543-8.
170.Sughrue ME, Connolly ES Jr.Effectively Bridging the Preclinical/Clinical Gap: The Results of the ASTIN Trial.Stroke,2004,35(4):e81-2.
171.Adams HP, Adams RJ,Brott T,del Zoppo GJ,et al;Stroke Council of the American Stroke Association.Guidelines for the early management of patients with ischemic stroke.A scientific statement from the stroke council of the Am Stroke Association.Stroke,2003,34(4):1056–83.
172.Molina CA,Saver JL.Extending reperfusion therapy for acute ischemic stroke:emerging pharmacological,mechanical,and imaging strategies.Stroke, 2005,36(10):2311-20.
173.Schwarz M, Nordt T, Bode C, Peter K.The GP IIb/IIIa inhibitor abciximab (c7E3) inhibits the binding of various ligands to the leukocyte integrin Mac-1 (CD11b/CD18).Thromb Res,2002,107(3-4):121–8.
174.Fintel DJ.From bench to bedside:GP IIb-IIIa inhibitors.Neurology,2001,57(5 Suppl 2):S12–9.
175.The Abciximab in Ischemic Stroke Investigators.Abciximab in acute ischemic stroke: a randomized, double-blind, placebo-controlled, dose-escalation study. Stroke,2000,31(3):601-9.
176.Abciximab Emergent Stroke Treatment Trial (AbESTT) Investigators.Emergency administration of abciximab for treatment of patients with acute ischemic stroke:results of a randomized phase 2 trial.Stroke,2005,36(4):880-90.
177. Ciccone A,Abraha I,Santilli I. Glycoprotein IIb-IIIa inhibitors for acute ischaemic stroke.Cochrane Database Syst Rev,2006, 18;(4):CD005208.
178. Mitsias PD,Lu M,Silver B,et al.MRI-guided,open trial of abciximab for ischemic stroke within a 3- to 24-hour window.Neurology,2005,65(4):612-5.
179.Heo JH, lee KY, Kim SH,et al.Immediate reocclusion following a successful thrombolysis in acute stroke:a pilot study.Neurology,2003, 60(10),1684–6.
180.Hofmann R,Kerschner K,Steinwender C,et al.Abciximab bolus injection does not reduce cerebral ischemic complications of elective carotid artery stenting:a randomized study.Stroke,2002,33(3):725–7.
181.Wholey MH, Eles G,Toursakissian B,et al.Evaluation of glycoprotein IIb/IIIa inhibitors in carotid angioplasty and stenting.J Endovasc Ther,2003,10(1): 33–41.
182.Bush RL,Lin PH, Bianco CC,et al.Carotid artery stenting in a community setting: experience outside of a clinical trial.Ann Vasc Surg,2003,17(6):629–34.
183.Lee DH,Jo KD,Kim HG,et al.Local intra-arterial urokinase thrombolysis of acute ischemic stroke with or without intravenous abciximab:a pilot study.J Vasc Interv Radiol,2002,13(8):769–73.
184.Morris DC, Silver B, Mitsias P,et al.Treatment of acute stroke with recombinant tissue plasminogen activator and abciximab.Acad Emerg Med,2003,10(12): 1396–1399.
185. Kopp CW,Steiner S,Nasel C,et al.Abciximab reduces monocyte tissue factor in carotid angioplasty and stenting.Stroke,2003,34(11):2560–7.
186. Qureshi AI,Harris-Lane P,Kirmani JF,et al.Intra-arterial reteplase and intravenous abciximab in patients with acute ischemic stroke:an open-label, dose-ranging,phase I study.Neurosurgery,2006,59(4):789-96.
187. Eckert B,Koch C,Thomalla G,et al.Aggressive therapy with intravenous abciximab and intra-arterial rtPA and additional PTA/stenting improves clinical outcome in acute vertebrobasilar occlusion:combined local fibrinolysis and intravenous abciximab in acute vertebrobasilar stroke treatment (FAST):results of a multicenter study.Stroke,2005,36(6):1160-5.
188.Abou-Chebl A,Bajzer CT,Krieger DW,et al.Multimodal therapy for the treatment of severe ischemic stroke combining GPIIb/IIIa antagonists and angioplasty after failure of thrombolysis.Stroke,2005,36(10):2286-8.
189.Gupta R,Vora NA,Horowitz MB,et al.Multimodal reperfusion therapy for acute ischemic stroke:factors predicting vessel recanalization.Stroke,2006,37(4): 986-90.
190.Velat GJ, Burry MV, Eskioglu E,et al.The use of abciximab in the treatment of acute cerebral thromboembolic events during neuroendovascular procedures.Surg Neurol,2006,65(4):352-8.
191.Junghans U,Seitz RJ,Aulich A,et al.Bleeding risk of tirofiban,a nonpeptide GPIIb/IIIa platelet receptor antagonist in progressive stroke: an open pilot study.Cerebrovasc Dis,2001,12(4):308–12.
192.Junghans U,Seitz RJ,Ritzl A,et al.Ischemic brain tissue salvaged from infarction by the GP IIb/IIIa platelet antagonist tirofiban.Neurology,2002,58(3):474–6.
193.Seitz RJ,Meisel S,Moll M,et al.The effect of combined thrombolysis with rtPA and tirofiban on ischemic brain lesions.Neurology,2004,62(11):2110–2.
194.Straub S,Junghans U,Jovanovic V,et al.Systemic thrombolysis with recombinant tissue plasminogen activator and tirofiban in acute middle cerebral artery occlusion.Stroke,2004,35(3):705–9.
195. Seitz RJ,Hamzavi M,Junghans U,et al.Thrombolysis with recombinant tissue plasminogen activator and tirofiban in stroke:preliminary observations. Stroke, 2003,34(8):1932-5.
196.Bukow SC,Daffertshofer M,Hennerici MG.Tirofiban for the treatment of ischaemic stroke.Expert Opin Pharmacother,2006,7(1):73-9.
197. Mangiafico S,Cellerini M,Nencini P,et al.Intravenous glycoprotein IIb/IIIainhibitor (tirofiban) followed by intra-arterial urokinase and mechanical thrombolysis in stroke.AJNR Am J Neuroradiol,2005,26(10):2595-601.
198. Mangiafico S,Cellerini M,Nencini P,et al.Intravenous tirofiban with intra-arterial urokinase and mechanical thrombolysis in stroke: preliminary experience in 11 cases.Stroke,2005,36(10):2154-8.
199.Junghans U,Siebler M.Cerebral microembolism is blocked by tirofiban,a selective nonpeptide platelet glycoprotein IIb/IIIa receptor antagonist.Circulation, 2003,107(21):2717-21.
200. Topol EJ,Easton D,Harrington RA,et al.Randomized,double-blind,placebo- controlled,international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease.Circulation,2003,108(4):399-406.
201. Wang WY,Wu YC,Wu CC.Prevention of platelet glycoprotein IIb/IIIa activation by 3,4-methylenedioxy-beta-nitrostyrene,a novel tyrosine kinase inhibitor.Mol Pharmacol,2006,70(4):1380-9.
202. Tanne D,Haim M,Boyko V,et al.Soluble intercellular adhesion molecule-1 and risk of future ischemic stroke:a nested case-control study from the Bezafibrate Infarction Prevention (BIP) study cohort.Stroke,2002,33(9):2182-6.
203.Kawamura T,Umemura T,Kanai A, et al.Soluble adhesion molecules and C-reactive protein in the progression of silent cerebral infarction in patients with type 2 diabetes mellitus.Metabolism,2006,55(4):461-6.
204.Jenny NS, Arnold AM, Kuller LH, et al.Soluble intracellular adhesion molecule-1 is associated with cardiovascular disease risk and mortality in older adults. J Thromb Haemost.2006,4(1):107-13.
205.夏斌,李莉,赵忠新,等.可溶性 ICAM-1 与脑梗死复发的前瞻性研究中华医学杂志.2005,85(18):1279-81.
206.Ehrensperger E,Minuk J,Durcan L,et al.Predictive value of soluble intercellular adhesion molecule-1 for risk of ischemic events in individuals with cerebrovascular disease.Cerebrovasc Dis,2005,20(6):456-62.
207.Campbell DJ,Woodward M,Chalmers JP,et al.Soluble Vascular Cell Adhesion Molecule 1 and N-terminal Pro–B-Type Natriuretic Peptide in Predicting Ischemic Stroke in Patients With Cerebrovascular Disease.Arch Neurol,2006, 63(1):60-65.
208.Heeringa J,Conway DS,van der Kuip DA,et al.A longitudinal population-based study of prothrombotic factors in elderly subjects with atrial fibrillation:the Rotterdam Study 1990-1999.J Thromb Haemost,2006,4(9):1944-9.
209.Volcik KA, Ballantyne CM, Coresh J,et al.P-selectin Thr715Pro polymorphism predicts P-selectin levels but not risk of incident coronary heart disease or ischemic stroke in a cohort of 14595 participants: the Atherosclerosis Risk in Communities Study.Atherosclerosis,2006,186(1):74-79.
210. Ferrari J,Rieger S,Endler G,et al.The Thr715Pro polymorphism of the P-selectin gene is not associated with ischemic stroke risk.Stroke,2007,38(2):395-7.
211. Pola R,Flex A,Gaetani E,et al.Synergistic Effect of -174 G/C Polymorphism of the Interleukin-6 Gene Promoter and 469 E/K Polymorphism of the IntercellularAdhesion Molecule-1 Gene in Italian Patients With History of Ischemic Stroke. Stroke,2003,34(4):881-5.
212.Bertges DJ,Muluk V,Whittle J,et al.Relevance of carotid stenosis progression as a predictor of ischemic neurological outcomes.Arch Intern Med,2003,163(19):2285–9.
213.Libby P,Ridker P,Maseri A.Inflammation and atherosclerosis.Circulation.2002, 105(9):1135–43.
214. Schillinger M,Exner M,Mlekusch W,et al,Inflammation and Carotid Artery—Risk for Atherosclerosis Study (ICARAS).Circulation,2005,111(17):2203-9.
215. Quehenberger O.Thematic review series:the immune system and atherogenesis. Molecular mechanisms regulating monocyte recruitment in atherosclerosis.J Lipid Res,2005,46(8):1582-90.
216.Hashimoto H,Kitagawa K,Kuwabara K,et al.Circulating adhesion molecules are correlated with ultrasonic assessment of carotid plaques.Clin Sci (Lond),2003, 104(5):521-7.
217.Amar J,Fauvel J,Drouet L,et al.Interleukin 6 is associated with subclinical atherosclerosis:a link with soluble intercellular adhesion molecule 1.J Hypertens,2006,24(6):1083-8.
218.Kondo K,Kitagawa K,Nagai Y,et al.Associations of soluble intercellular adhesion molecule-1 with carotid atherosclerosis progression.Atherosclerosis,2005, 179(1):155-60.
219.Hulthe J,Wikstrand J,Mattsson-Hulten L,et al.Circulating ICAM-1 (intercellular cell-adhesion molecule 1) is associated with early stages of atherosclerosis development and with inflammatory cytokines in healthy 58-year-old men:the Atherosclerosis and Insulin Resistance (AIR) study.Clin Sci (Lond),2002, 103(2):123-9.
220.Larsson PT,Hallerstam S,Rosfors S,et al.Circulating markers of inflammation are related to carotid artery atherosclerosis.Int Angiol,2005,24(1):43-51.
221. Chironi G,Dosquet C,Del-Pino M,et al.Relationship of circulating biomarkers of inflammation and hemostasis with preclinical atherosclerotic burden in nonsmoking hypercholesterolemic men.Am J Hypertens,2006,19(10):1025-31.
222.Koyama H,Maeno T,Fukumoto S,et al.Platelet P-selectin expression is associated with atherosclerotic wall thickness in carotid artery in humans.Circulation, 2003,108(5):524-9.
223.Yip HK,Lu CH,Yang CH,et al.Levels and value of platelet activity in patients with severe internal carotid artery stenosis. Neurology,2006,66(6):804-8.
224. McCabe DJ,Harrison P,Mackie IJ, et al.Increased platelet count and leucocyte-platelet complex formation in acute symptomatic compared with asymptomatic severe carotid stenosis.J Neurol Neurosurg Psychiatry,2005,76(9): 1249-54.
225.Shoji T,Koyama H,Fukumoto S,et al.Platelet-monocyte aggregates are independently associated with occurrence of carotid plaques in type 2 diabeticpatients.J Atheroscler Thromb,2005,12(6):344-52.
226.Testa A,Benedetto FA,Spoto B,et al.The E-selectin gene polymorphism and carotid atherosclerosis in end-stage renal disease.Nephrol Dial Transplant,2006, 21(7):1921-6.
227. Yang PY, Rui YC.Intercellular adhesion molecule-1 and vascular endothelial growth factor expression kinetics in macrophage-derived foam cells.Life Sci,2003,74(4):471-80.
228. Yang PY, Almofti MR, Lu L,et al.Reduction of atherosclerosis in cholesterol-fed rabbits and decrease of expressions of intracellular adhesion molecule-1 and vascular endothelial growth factor in foam cells by a water-soluble fraction of Polygonum multiflorum.J Pharmacol Sci,2005,99(3):294-300.
229. Yoshii T,Iwai M,Li Z,et al.Regression of atherosclerosis by amlodipine via anti-inflammatory and anti-oxidative stress actions.Hypertens Res,2006,29(6): 457-66.
230. Zhu S,Su G,Meng QH.Inhibitory effects of micronized fenofibrate on carotid atherosclerosis in patients with essential hypertension.Clin Chem,2006, 52(11):2036-42.
231.Sumino H,Ichikawa S,Kasama S,et al.Effect of transdermal hormone replacement therapy on carotid artery wall thickness and levels of vascular inflammatory markers in postmenopausal women.Hypertens Res,2005,28(7):579-84.
232. Nadar SK,Blann AD,Kamath S,et al.Platelet indexes in relation to target organ damage in high-risk hypertensive patients: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT).J Am Coll Cardiol,2004,44(2):415-22.
233.Glowinska B,Urban M,Peczynska J,et al.Soluble adhesion molecules (sICAM-1, sVCAM-1) and selectins (sE selectin, sP selectin, sL selectin) levels in children and adolescents with obesity,hypertension,and diabetes.Metabolism, 2005,54(8):1020-6.
234. Nadar S,Blann AD,Lip GY. Platelet morphology and plasma indices of platelet activation in essential hypertension:effects of amlodipine-based antihypertensive therapy.Ann Med,2004,6(7):552-7.
235.Sironi L,Gianazza E,Gelosa P,et al.Rosuvastatin,but not simvastatin,provides end-organ protection in stroke-prone rats by antiinflammatory effects. Arterioscler Thromb Vasc Biol,2005,25(3):598-603.
236.Hoogeveen RC,Ballantyne CM,Bang H,et al.Circulating oxidised low-density lipoprotein and intercellular adhesion molecule-1 and risk of type 2 diabetes mellitus:the Atherosclerosis Risk in Communities Study.Diabetologia,2007, 50(1):36-42.
237.Soedamah-Muthu SS,Chaturvedi N,Schalkwijk CG,et al.Soluble vascular cell adhesion molecule-1 and soluble E-selectin are associated with micro- and macrovascular complications in Type 1 diabetic patients.J Diabetes Complications,2006,20(3):188-95.
238.Hu H,Hjemdahl P,Li N.Effects of insulin on platelet and leukocyte activity inwhole blood.Thromb Res,2002,107(5):209-15.
239.Kent JW Jr,Comuzzie AG,Mahaney MC,et al.Intercellular adhesion molecule-1 concentration is genetically correlated with insulin resistance,obesity,and HDL concentration in Mexican Americans.Diabetes,2004,53(10):2691-5.
240. Yip HK,Wu CJ,Hang CL,et al.Levels and values of inflammatory markers in patients with angina pectoris.Int Heart J,2005,46(4):571-81.
241.Turhan H,Saydam GS,Erbay AR,et al.Increased plasma soluble adhesion molecules; ICAM-1, VCAM-1, and E-selectin levels in patients with slow coronary flow.Int J Cardiol,2006,108(2):224-30.
242. Fang L, Wei H, Mak KH, et al.Markers of low-grade inflammation and soluble cell adhesion molecules in Chinese patients with coronary artery disease.Can J Cardiol,2004,20(14):1433-8.
243.Skilton MR, Nakhla S,Sieveking DP,et al. Pathophysiological levels of the obesity related peptides resistin and ghrelin increase adhesion molecule expression on human vascular endothelial cells.Clin Exp Pharmacol Physiol,2005,32(10):839-44.
244.Sejda T,Jedliekova V,Svandova E,et al.The effect of fluvastatin on cICAM-1 as a biomarker of endothelial dysfunction in patients with dyslipidemia.Int Angiol,2006,25(4):414-7.
245.Zeller JA, Frahm K,Baron R,et al.Platelet-leukocyte interaction and platelet activation in migraine:a link to ischemic stroke?J Neurol Neurosurg Psychiatry,2004,75(7):984-7.
246.Mayberg MR.Cerebral vasospasm.Neurosurg Clin N Am,1998,9(3): 615–27.
247.Feigin VL,Rinkel GJ,Algra A,et al.Calcium antagonists in patients with aneurysmal subarachnoid hemorrhage:a systematic review.Neurology,1998,50(4): 876–83.
248.Thai QA,Oshiro EM,Tamargo RJ.Inhibition of experimental vasospasm in rats with the periadventitial administration of ibuprofen using controlled-release polymers.Stroke,1999,30(1):140–7.
249.Bavbek M,Polin R,Kwan AL,et al.Monoclonal antibodies against ICAM-1 and CD18 attenuate cerebral vasospasm after experimental subarachnoid hemorrhage in rabbits.Stroke,1998,29(9):1930–5.
250.Oshiro EM,Hoffman PA,Dietsch GN,et al.Inhibition of experimental vasospasm with anti-intercellular adhesion molecule-1 monoclonal antibody in rats.Stroke, 1997.28(10):2031–7.
251.Sills AKJ,Clatterbuck RE,Thompson RC,et al.Endothelial cell expression of intercellular adhesion molecule 1 in experimental posthemorrhagic vasospasm. Neurosurgery,1997,41(2):453–60.
252. Tanriverdi T,Kafadar AM,et al.Detection of soluble intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in both cerebrospinal fluid and serum of patients after aneurysmal subarachnoid hemorrhage.J Neurosurg, 2004,101(6):1030-6.
253.Mack WJ,Mocco J,Hoh DJ,et al.Outcome prediction with serum intercellular adhesion molecule-1 levels after aneurysmal subarachnoid hemorrhage.JNeurosurg,2002,96(1):71–5.
254.Mocco J,Mack WJ,Kim GH,et al. Rise in serum soluble intercellular adhesion molecule-1 levels with vasospasm following aneurysmal subarachnoid hemorrhage. J Neurosurg,2002,97(3):537-41
255. Rothoerl RD,Schebesch KM,Kubitza M,et al.ICAM-1 and VCAM-1 expression following aneurysmal subarachnoid hemorrhage and their possible role in the pathophysiology of subsequent ischemic deficits.Cerebrovasc Dis,2006,22(2-3): 143-9.
256.Frijns CJ,Fijnheer R,Algra A,et al.Early circulating levels of endothelial cell activation markers in aneurysmal subarachnoid haemorrhage:associations with cerebral ischaemic events and outcome. J Neurol Neurosurg Psychiatry,2006, 77(1):77-83.
257. Frijns CJ,Kasius KM,Algra A,et al.Endothelial cell activation markers and delayed cerebral ischaemia in patients with subarachnoid haemorrhage.J Neurol Neurosurg Psychiatry,2006,77(7):863-7.
258.Pradilla G,Wang PP,Legnani FG,et al.Prevention of vasospasm by anti-CD11/CD18 monoclonal antibody therapy following subarachnoid hemorrhage in rabbits.J Neurosurg,2004,101(1):88-92.
259. Lin CL,Dumont AS,Calisaneller T,et al.Monoclonal antibody against E selectin attenuates subarachnoid hemorrhage-induced cerebral vasospasm.Surg Neurol, 2005,64(3):201-5.
260.Lindsberg PJ,Roine RO,Tatlisumak T,et al.The future of stroke treatment.Neurol Clin,2000,18():495–510.
261.Nahrendorf M,Jaffer FA,Kelly KA,et al.Noninvasive vascular cell adhesion molecule-1 imaging identifies inflammatory activation of cells in atherosclerosis.Circulation,2006,114(14):1504-11.
2. 黄铮,龚兰生,施仲伟,等.冠心病患者颈动脉粥样硬化斑块的好发部位及超声分型.中国超声医学杂志,1996,12(5):34-7.
3. 王 建 中 , 孙 市 , 王 淑 娟 , 等 . 流 式 细 胞 术 检 测 活 化 血 小 板 . 中 华 医 学 检 验 杂志,1994,17(4):232-5.
4. Rinder HM,Bonan JL,Rinder CS,et al.Activated and unactivated platelet adhesion to monocytes and neutrophils.Blood,1991,78(7):1760-9.
5. Ott I,Neumann FJ,Gawaz M et al.Increased neutrophil platelet adhesion in patients with unstable angina.Circulation,1996,94(6):1239-44.
6. Mickelson JK,Lakkis NM,Villarreal-Levy G,et al.Leukocyte activation with platelet adhesion after coronary angioplasty:a mechanism for recurrent disease? J Am Coll Cardiol,1996,28(2):345-53.
7. Chakhtoura EY,Shamoon FE,Haft JI,et al.Comparison of platelet activation in unstable and stable angina pectoris and correlation with coronary angiographic findings.Am J Cardiol,2000,86(8):835-9.
8. Ramsis N,El-Hawary AA,Ismail E.Relation between carotid intima-media thickness, platelet surface activation and endothelial cell markers.Haemostasis,1998, 28(5):268-75.
9. Furman MI,Benoit SE,Barnard MR,et al.Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease.J Am Coll Cardiol,1998,31(2):352-8.
10. Michelson AD,Barnard MR,Krueger LA,et al.Evaluation of platelet function by flow cytometry.Methods,2000,21(3):259-70.
11. Nadar SK,Blann AD,Kamath S,et al.Platelet indexes in relation to target organdamage in high-risk hypertensive patients: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT).J Am Coll Cardiol,2004,44(2):415-22..
12. Holme PA,Orvim U,Hamers MJ,et al.Shear-induced platelet activation and platelet microparticle formation at blood flow conditions as in arteries with a severe stenosis. Arterioscler Thromb Vasc Biol,1997,17(4):646-53.
13. Kawano H,Tsuji H,Nishimura H,et al.Serotonin induces the expression of tissue factor and plasminogen activator inhibitor-1 in cultured rat aortic endothelial cells. Blood 2001,97(6):1697-702.
14. Gawaz M, Brand K, Dickfeld T, et al. Platelets induce alterations of chemotactic and adhesive properties of endothelial cells mediated through an interleukin-1 -dependent mechanism.Atherosclerosis,2000,48(1):75-85.
15. Yip HK,Chen SS,Liu JS,et al.Serial changes in platelet activation in patients after ischemic stroke:role of pharmacodynamic modulation.Stroke,2004,35(7): 1683-7.
16. Wallaschofski H,Lohmann T,Hild E,et al.Enhanced platelet activation by prolactin in patients with ischemic stroke.Thromb Haemost,2006,96(1):38-44.
1. Golledge J,Greenhalgh RM,Davies AH.The symptomatic carotid plaque.Stroke, 2000,31(3):774-81.
2. Schumacher H,Kaiser E,Schnabel PA,et al.Immunophenotypic characterisation of carotid plaque:increased amount of inflammatory cells as an independent predictor for ischaemic symptoms.Eur J Vasc Endovasc Surg,2001,21(6):494-501.
3. 中华神经科学会 中华神经外科学会.各类脑血管疾病诊断要点.中华神经科杂志,1996,29(6):379-80.
4. 黄铮,龚兰生,施仲伟,等.冠心病患者颈动脉粥样硬化斑块的好发部位及超声分型.中国超声医学杂志,1996,12(5):34-7.
5. Schillinger M,Exner M,Mlekusch W,et al.Inflammation and Carotid Artery--Risk for Atherosclerosis Study (ICARAS).Circulation,2005,111(17):2203-9.
6. Kiechl S,Egger G,Mayr M,et al.Chronic infections and the risk of carotid atherosclerosis: prospective results from a large population study.Circulation, 2001,103(8):1064-70.
7. Elkind MS,Cheng J,Boden-Albala B,et al.Elevated white blood cell count and carotid plaque thickness:the northern manhattan stroke study.Stroke,2001, 32(4):842-9.
8. Hashimoto H,Kitagawa K,Kuwabara K,et al.Circulating adhesion molecules are correlated with ultrasonic assessment of carotid plaques.Clin Sci (Lond),2003, 104(5):521-7.
9. Rohde LE,Lee RT,Rivero J,et al.Circulating cell adhesion molecules are correlated with ultrasound-based assessment of carotid atherosclerosis. Arterioscler Thromb Vasc Biol,1998,18(11):1765-70.
10. Kondo K,Kitagawa K,Nagai Y,et al.Associations of soluble intercellular adhesion molecule-1 with carotid atherosclerosis progression.Atherosclerosis,2005, 179(1):155-60.
11. McCabe DJ,Harrison P,Mackie IJ, et al.Increased platelet count and leucocyte-platelet complex formation in acute symptomatic compared with asymptomatic severe carotid stenosis.J Neurol Neurosurg Psychiatry,2005,76(9): 1249-54.
12. Shoji T,Koyama H,Fukumoto S,et al.Platelet-monocyte aggregates are independently associated with occurrence of carotid plaques in type 2 diabeticpatients.J Atheroscler Thromb,2005,12(6):344-52.
13. Galante A, Pietroiusti A, Magrini A, et al.Leucocyte rheological properties are altered in patients with diffuse atherosclerosis.Thromb Haemost,1997, 77(6):1073-6.
14. Blankenberg S,Barbaux S,Tiret L.Adhesion molecules and atherosclerosis. Atherosclerosis.2003,170(2):191-203.
15. Mocco J,Choudhri TF,Mack WJ,et al.Elevation of soluble intercellular adhesion molecule-1 levels in symptomatic and asymptomatic carotid atherosclerosis. Neurosurgery,2001,48(4):718-21.
16. Glowinska B,Urban M,Peczynska J,et al.Soluble adhesion molecules (sICAM-1, sVCAM-1) and selectins (sE selectin, sP selectin, sL selectin) levels in children and adolescents with obesity,hypertension,and diabetes.Metabolism, 2005,54(8):1020-6.
17. Blankenberg S,Barbaux S,Tiret L.Adhesion molecules and atherosclerosis. Atherosclerosis.2003,170(2):191-203.
18. Oguchi S,Dimayuga P,Zhu J,et al.Monoclonal antibody against vascular cell adhesion molecule-1 inhibits neointimal formation after periadventitial carotid artery injury in genetically hypercholesterolemic mice.Arterioscler Thromb Vasc Biol,2000,20(7):1729-36.
19. Htun P,Fateh-Moghadam S,Tomandl B,et al.Course of platelet activation and platelet-leukocyte interaction in cerebrovascular ischemia.Stroke,2006,37(9): 2283-7.
20. Kurabayashi H,Tamura J,Naruse T,et al.Possible existence of platelet activation before the onset of cerebral infarction.Atherosclerosis,2000,153(1):203-7.
21. Furman MI,Benoit SE,Barnard MR,et al.Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease.J Am Coll Cardiol,1998,31(2):352-8.
22. Yang PY, Almofti MR, Lu L,et al.Reduction of atherosclerosis in cholesterol-fed rabbits and decrease of expressions of intracellular adhesion molecule-1 and vascular endothelial growth factor in foam cells by a water-soluble fractionof Polygonum multiflorum.J Pharmacol Sci,2005,99(3):294-300.
23. Barnett HJ, Meldrum HE.Endarterectomy for carotid stenosis:new approaches in patient selection.Cerebrovasc Dis,2001,11 (Suppl 1):105-11.
1 Petty GW,Brown RD Jr,Whisnant JP,et al.Survival and recurrence after first cerebral infarction:a population-based study in Rochester,Minnesota,1975 through 1989.Neurology,1998,50(1):208-16.
2 Malik I,Danesh J,Whincup P,et al.Soluble adhesion molecules and prediction of coronary heart disease:a prospective study and meta-analysis.Lancet,2001, 358(9286):971–5.
3 Tanne D,Haim M,Boyko V,et al.Soluble intercellular adhesion molecule-1 and risk of future ischaemic stroke: a nested case-control study from the Bezafibrate Infarction Prevention (BIP) study cohort.Stroke,2002,33(9):2182–6.
4 Kawamura T,Umemura T,Kanai A, et al.Soluble adhesion molecules and C-reactive protein in the progression of silent cerebral infarction in patients with type
2 diabetes mellitus.Metabolism,2006,55(4):461-6.
5 Jenny NS, Arnold AM, Kuller LH, et al.Soluble intracellular adhesion molecule-1 is associated with cardiovascular disease risk and mortality in older adults. J Thromb Haemost.2006,4(1):107-13.
6 中华神经科学会 中华神经外科学会.各类脑血管疾病诊断要点.中华神经科杂志,1996,29(6):379-380.
7 夏斌,邵福源,赵忠新,等.急性缺血性脑血管病患者血清可溶性黏附分子的变化.上海医学,2002,25(5):308-9.
8 Sheinart KF,Tuhrim S,Horowitz DR,et al.Stroke recurrence is more frequent in Blacks and Hispanics.Neuroepidemiology,1998,17(4):188-98.
9 Appelros P,Nydevik I,Viitanen M.Poor outcome after first-ever stroke:predictors for death,dependency,and recurrent stroke within the first year.Stroke, 2003,34(1):122-6.
10 Blankenberg S,Barbaux S,Tiret L.Adhesion molecules and atherosclerosis. Atherosclerosis,2003,170(2):191-203.
11 Preston RA,Ledford M,Materson BJ,et al.Effects of severe, uncontrolled hypertension on endothelial activation:soluble vascular cell adhesion molecule-1, soluble intercellular adhesion molecule-1 and von Willebrand factor.J Hypertens,2002,20(5):871-7.
12 Takeuchi N,Kawamura T,Kanai A,et al.The effect of cigarette smoking on soluble adhesion molecules in middle-aged patients with Type 2 diabetes mellitus.Diabet Med,2002,19(1):57-64.
13 Romano M,Mezzetti A,Marulli C,et al.Fluvastatin reduces soluble P-selectin and ICAM-1 levels in hypercholesterolemic patients: role of nitric oxide.J Investig Med,2000,48(3):183-9.
14 Libby P,Ridker PM,Maseri A.Inflammation and atherosclerosis.Circulation,2002, 105(9):1135-43.
15 Golledge J,Greenhalgh RM,Davies AH.The symptomatic carotid plaque.Stroke, 2000,31(3):774-81.
16 DeGraba TJ,Siren AL,Penix L,et al.Increased endothelial expression of intercellular adhesion molecule-1 in symptomatic versus asymptomatic human carotid atherosclerotic plaque.Stroke.1998,29(7):1405–10.
17 Mocco J,Choudhri TF,Mack WJ,et al.Elevation of soluble intercellular adhesion molecule-1 levels in symptomatic and asymptomatic carotid atherosclerosis. Neurosurgery,2001,48(4):718-21.
18 Nawawi H,Osman NS,Annuar R,et al.Soluble intercellular adhesion molecule-1 and interleukin-6 levels reflect endothelial dysfunction in patients with primaryhypercholesterolaemia treated with atorvastatin.Atherosclerosis,2003,169(2): 283-91.
19 Kowalski J,Okopien B,Madej A,et al.Effects of fenofibrate and simvastatin on plasma sICAM-1 and MCP-1 concentrations in patients with hyperlipoproteinemia. Int J Clin Pharmacol Ther,2003,41(6):241-7.
1. 夏斌,张玲珍,邵福源,等.缺血性卒中患者白细胞CD11b和CD18表达的动态观察.中风与神经疾病杂志,2000,17(2):85-7.
2. 夏斌,张玲珍,邵福源,等.缺血性卒中患者白细胞粘附分子的表达.中国神经精神疾病杂,2000,26(5):310-1.
3. Xia Bin,Shao Fuyuan,Zhao Zhongxin.Dynamic observation of the levels of sICAM-1 and sVCAM-1 in the patients with acute ischemic stroke. 中国临床 神经科学,2000,8(增刊):73.
4. 夏斌,张玲珍,邵福源,等.急性缺血性脑卒中患者血小板膜糖蛋白的表达.中华老年医学杂志,1999,18(6):337-9.
5. 夏斌,张玲珍,邵福源,等.缺血性卒中患者血小板-白细胞粘附性的变化.中华老年医学杂志,2000,19(3):223-4.
6. 中华神经科学会 中华神经外科学会.各类脑血管疾病诊断要点.中华神经科杂志,1996,29(6):379-80.
7. 陈清棠,赵玉宾,郑亚文,等.巴曲酶注射液治疗急性脑梗死的临床实验.中风与神经疾病杂志,2000,17(1):27-30.
8. Xu G,Liu X,Zhu W,et al.Feasibility of treating hyperfibrinogenemia with intermittently administered batroxobin in patients with ischemic stroke/transient ischemic attack for secondary prevention.Blood Coagul Fibrinolysis,2007,18(2):193-7.
9. Wu W,Kuang P,Jiang S,et al.Effects of batroxobin on spatial learning and memory disorder of rats with temporal ischemia and the expression of HSP32 and HSP70. J Tradit Chin Med,2000,20(4):297-301.
10. 苏志强,刘亢丁,饶明俐.不同剂量巴曲酶对大鼠局灶性脑缺血再灌流后细胞凋亡的影响.中风与神经疾病杂志.2001,18(1):12-3.
11. 潘钰, 丛琳,张朝东.巴曲酶治疗糖尿病大鼠局灶性脑缺血再灌注损伤的实验研究.中国康复理论与实践,2004,10 (9):526-8.
12. 李振光,伍期专,姚存姗.脑梗死小鼠凋亡神经元及脑血管内皮细胞超微结构的观察.中华老年心血管杂志,2000,2(2):128.
13. 郭志权,张泉静,张晓华.东菱克栓酶、尿激酶对沙土鼠脑缺血再灌注模型白细胞与内皮细胞粘附抑制的实验观察.山西医科大学学报,2000,31(3):199-201.
14. Kato H, Kogure K, Liu XH, et al. Progressive expression of immunomolecules on activated microglia and invading leukocytes following focal cerebral ischemia in the rat.Brain Res,1996,734(1-2):203-212.
15. Price CJ,Menon DK,Peters AM,et al.Cerebral Neutrophil Recruitment, Histology, and Outcome in Acute Ischemic Stroke.Stroke,2004,35(7):1659-64.
16. Zhang RL,Zhang ZG,Chopp M,et al. Thrombolysis with tissue plasminogen activator alters adhesion molecule expression in the ischemic rat brain.Stroke, 1999,30(3):624-9.
17. Michelson AD,Barnard MR,Krueger LA,et al.Evaluation of platelet function by flow cytometry.Methods,2000,21(3):259-70.
18. Kawano K,Aoki I,Aoki N,et al. Human platelet activation by thrombolytic agents:effects of tissue-type plasminogen activator and urokinase on platelet surface P-selectin expression.Am Heart J,1998,135:268-71.
19. Coulter SA,Cannon CP,Ault KA,et al.High levels of platelet inhibition with abciximab despite heightened platelet activation and aggregation during thrombolysis for acute myocardial infarction:results from TIMI (thrombolysis in myocardial infarction).Circulation,2000,101(23):2690-5.
20. 曹茂红,柯开富.巴曲酶联合抗血小板聚集药治疗急性脑梗死的疗效观察.临床神经病学杂志,2006,19(2):141-3.
1. Schumacher H,Kaiser E,Schnabel PA,et al.Immunophenotypic characterisation of carotid plaque:increased amount of inflammatory cells as an independent predictor for ischaemic symptoms.Eur J Vasc Endovasc Surg,2001,21(6):494-501.
2. 夏斌,赵忠新,方平,等.伴脑梗死颈动脉粥样硬化与血小板激活的关系.上海医学,2003,26(3):197-199.
3. 黄铮,龚兰生,施仲伟,等.冠心病患者颈动脉粥样硬化斑块的好发部位及超声分型.中国超声医学杂志,1996,12(5):34-37.
4. 夏斌,张玲珍,邵福源,等.急性缺血性脑卒中患者血小板膜糖蛋白的表达.中华老年医学杂志,1999,18(6):337-339.
5. 夏斌,张玲珍,邵福源,等.缺血性卒中患者血小板-白细胞粘附性的变化.中华老年医学杂志, 2000,19(3):223-223.
6. Furman MI,Benoit SE,Barnard MR,et al.Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease.J Am Coll Cardiol,1998,31(2):352-358.
7. Kaplar M,Kappelmayer J,Veszpremi A,et al.The possible association of in vivo leukocyte-platelet heterophilic aggregate formation and the development of diabetic angiopathy.Platelets,2001,12(7):419-422.
8. Golledge J,Greenhalgh RM,Davies AH.The symptomatic carotid plaque. Stroke,2000,31(3):774-781.
9. 史载祥,任在方,黄力,等.通心络胶囊对急性脑梗死患者血浆 D-D 聚体、plg、AT-Ⅲ含量的影响.浙江中西医结合杂志,2002,12:471-472.
10. Kawano H,Tsuji H,Nishimura H,et al.Serotonin induces the expression of tissue factor and plasminogen activator inhibitor-1 in cultured rat aortic endothelial cells.Blood 2001,97(6):1697-1702.
1. Frijns CJ,Kappelle LJ.Inflammatory cell adhesion molecules in ischemic cerebrovascular disease.Stroke,2002,33(8):2115-2122.
2. 董志领,邵汝生,李建华,等.通心络胶囊治疗脑梗塞临床观察.中国中医基础医学杂志,2001,7:(4):66-67.
3. Longa EZ,Weinstein PR,Carlson S,et al. Reversible middle cerebral artery occlusion without craniectomy in rats.Stroke,1989,20(1):84-91.
4. Ding Y,Li J,Rafols JA,et al.Prereperfusion saline infusion into ischemic territory reduces inflammatory injury after transient middle cerebral artery occlusion in rats.Stroke,2002,33(10):2492-2498.
5. Zhang RL,Chopp M,Zaloga C,,et al.The temporal profiles of ICAM-1 protein and mRNA expression after transient MCA occlusion in the rat.Brain Res,1995,682(1-2):182-188.
6. Justicia C,Martin A,Rojas S,et al.Anti-VCAM-1 antibodies did not protect against ischemic damage either in rats or in mice.J Cereb Blood Flow Metab,2006,26(3):421-432
7. 周东华,张莉莉,陈曼娥.脑缺血再灌注 ICAM-1 的表达与神经元损伤.第三军医大学学报,2000,22(2):115-118.
8. 王中孝,蔡竖平,徐洁.脑缺血/再灌注脑微血管内皮细胞 ELAM-1 和 ICAM-1mRNA 表达的研究.中国应用生理学杂志,2001,17(3):236-238.
9. 雷万龙,刘勇,袁群芳,等.大鼠局部脑缺血区 VCAM-1 表达和单核/巨噬细胞浸润的研究.中华微生物学和免疫学杂志,2000,20(2):105.
10. 周东华,邓娟,陈曼娥.通心络胶囊对脑缺血-再灌注大鼠保护作用的实验研究.中国急救医学.2001,21(8):435-437.
11. Furuya K,Takeda H,Azhar S,et al.Examination of several potential mechanisms for the negative outcome in a clinical stroke trial of enlimomab, a murine anti-human intercellular adhesion molecule-1 antibody: a bedside-to-bench study. Stroke,2001,32(11):2665-2674.
1. Huang J,Upadhyay UM,Tamargo RJ.Inflammation in stroke and focal cerebral ischemia.Surg Neurol,2006,66(3):232-45.
2. Gee JM,Kalil A,Shea C,et al.Lymphocytes:Potential Mediators of Postischemic Injury and Neuroprotection.Stroke,2007,38(2):783–8.
3. Frijns CJ,Kappelle LJ.Inflammatory cell adhesion molecules in ischemic cerebrovascular disease.Stroke,2002,33(8):2115–22.
4. Blankenberg S,Barbaux S,Tiret L.Adhesion molecules and atherosclerosis. Atherosclerosis.2003,170(2):191-203.
5. Quehenberger O.Thematic review series:the immune system and atherogenesis. Molecular mechanisms regulating monocyte recruitment in atherosclerosis.J Lipid Res,2005,46(8):1582-90.
6. Hafezi-Moghadam A,Thomas KL,Prorock AJ,et al.L-selectin shedding regulates leukocyte recruitment.J Exp Med,2001,193(7):863–72.
7. Leeuwenberg JF,Smeets EF,Neefjes JJ,et al.E-selectin and intercellular adhesion molecule-1 are released by activated human endothelial cells in vitro.Immunology,1992,77(4):543-9.
8. Ishiwata N,Takio K,Katayama M, et al. Alternatively spliced isoform of P-selectin is present in vivo as a soluble molecule.J Biol Chem,1994,269 (38):23708–15.
9. Berger G,Hartwell DW,Wagner DD.P-Selectin and platelet clearance.Blood,1998,92(11):4446-52.
10. Sako D,Chang XJ,Barone KM,et al.Expression cloning of a functionalalligand for P-selectin. Cell,1993,75(6):1179-86.
11. Norman KE,Katopodis AG,Thoma G,et al. P-selectin glycoprotein ligand-1 supports rolling on E- and P-selectin in vivo.Blood,2000,96(10): 3585–91.
12. Steegmaier M,Levinovitz A,Isenmann S, et al. The E-selectin-ligand ESL-1 is a variant of a receptor for fibroblast growth factor.Nature,1995,373 (6515): 615–20.
13. Kansas GS. Selectins and their ligands:current concepts and controversies. Blood,1996,88(9):3259–87.
14. Warnock RA,Askari S,Butcher EC,et al.Molecular mechanisms of lymphocyte homing to peripheral lymph nodes.J Exp Med,1998,187(2):205–16.
15. Leeuwenberg JF,Smeets EF,Neefjes JJ,et al.E-selectin and intercellular adhesion molecule-1 are released by activated human endothelial cells in vitro. Immunology,1992,77 (4):543–9.
16. del Pozo MA,Pulido R,Munoz C, et al. Regulation of ICAM-3 (CD50) membrane expression on human neutrophils through a proteolytic shedding mechanism. Eur. J. Immunol,1994,24(11):2586–94.
17. Champagne B,Tremblay P,Cantin A, et al. Proteolytic cleavage of ICAM-1 by human neutrophil elastase.J Immunol,1998,161(11):6398–405.
18. Fiore E,Fusco C,Romero P,et al.Matrix metalloproteinase 9 (MMP-9/gelatinase B) proteolytically cleaves ICAM-1 and participates in tumor cell resistance to natural killer cell-mediated cytotoxicity.Oncogene,2002,21(34):5213–23.
19. Matheny HE,Deem TL,Cook-Mills JM.Lymphocyte migration through monolayers of endothelial cell lines involves VCAM-1 signaling via endothelial cell NADPH oxidase.J Immunol,2000,164(12):6550–9.
20. Leca G,Mansur SE,Bensussan A.Expression of VCAM-1 (CD106) by a subset of TCR gamma delta-bearing lymphocyte clones.Involvement of a metalloprotase in the specific hydrolytic release of the soluble isoform.J Immunol,1995,154 (3): 1069–77.
21. Newton JP, Buckley CD,Jones EY,et al.Residues on both faces of the first immunoglobulin fold contribute to homophilic binding sites of PECAM-1/CD31. J Biol Chem,1997,272(33):20555–63.
22. Goldberger A, Middleton KA,Oliver JA,et al. Biosynthesis and processing of the cell adhesion molecule PECAM-1 includes production of a soluble form.J Biol Chem,1994,269(25):17183-91.
23. Hughes PE,Pfaff M.Integrin affinity modulation.Trends Cell Biol,1998,8(9): 359-64.
24. Lynam E, Sklar LA,Taylor AD,et al.Beta2-integrins mediate stable adhesion in collisional interactions between neutrophils and ICAM-1-expressing cells.J Leukocyte Biol,1998,64(5):622–30.
25. Lefer AM.Role of the beta2-integrins and immunoglobulin superfamily members in myocardial ischemia-reperfusion.Ann.Thorac Surg,1999,68(15):1920–3.
26. Rose DM,Grabovsky V,Alon R,et al.The affinity of integrin alpha(4)beta(1)governs lymphocyte migration.J Immunol,2001,167(5):2824–30.
27. Moiseeva EP. Adhesion receptors of vascular smooth muscle cells and their functions.Cardiovasc Res,2001,52(3):372–86.
28. Cines DB,Pollak ES, Buck CA,et al.Endothelial cells in physiology and in the pathophysiology of vascular disorders.Blood,1998,91(10):3527–61.
29. Somers WS,Tang J, Shaw GD, et al.Insights into the molecular basis of leukocyte tethering and rolling revealed by structures of P- and E-selectin bound to SLe(X) and PSGL-1.Cell,2000,103(3):467–79.
30. Ohmori K,Kanda K,Mitsuoka C,et al.P- and E-selectins recognize sialyl 6-sulfo Lewis X,the recently identified L-selectin ligand.Biochem Biophys Res Commun, 2000,278(1):90–6.
31. Carlos TM, Harlan JM.Leukocyte-endothelial adhesion molecules. Blood, 1994,84(7): 2068–101.
32. Clark WM, Zivin JA.Antileukocyte adhesion therapy:preclinical trials and combination therapy.Neurology,1997,49(suppl 4):S32–S38.
33. Jean WC,Spellman SR,Nussbaum ES,et al.Reperfusion injury after focal cerebral ischemia:the role of inflammation and the therapeutic horizon. Neurosurgery, 1998,43(6):1382–96.
34. Matsuo Y,Onodera H,Shiga Y,et al.Correlation between myeloperoxidase -quantified neutrophil accumulation and ischemic brain injury in the rat: effects of neutrophil depletion.Stroke,1994,25(7):1469–75.
35. Kochanek PM,Hallenbeck JM.Polymorphonuclear leukocytes and monocytes /macrophages in the pathogenesis of cerebral ischemia and stroke.Stroke, 1992,23(9):1367–79.
36. Mori E,del Zoppo GJ,Chambers JD,et al. Inhibition of polymorphonuclear leukocyte adherence suppresses no-reflow after focal cerebral ischemia in baboons.Stroke,1992,23(5):712–8.
37. Dutka AJ,Kochanek PM,Hallenbeck JM.Influence of granulocytopenia on canine cerebral ischemia induced by air embolism.Stroke,1989,20(3):390–5.
38. Hallenbeck JM,Dutka AJ,Tanishima T,et al. Polymorphonuclear leukocyte accumulation in brain regions with low blood flow during the early postischemic period.Stroke,1986,17(2):246–53.
39. Prentice RL,Szatrowski TP, Kato H,et al.Leukocyte counts and cerebrovascular disease.J Chron Dis,1982,35 (9):703–14.
40. Bednar MM,Gross CE,Balazy M,et al.Antineutrophil strategies. Neurology,1997,49 (suppl 4):S20–S22.
41. Pozzilli C,Lenzi GL Argentino C,et al.Imaging of leukocytic infiltration in human cerebral infarcts.Stroke,1985,16(2):251–5.
42. Emerich DF, Dean RL,Bartus RT.The role of leukocytes following cerebral ischemia: pathogenic variable or bystander reaction to emerging infarct? Exp Neurol,2002,173(1): 168–81.
43. Barone FC, Feuerstein GZ.Inflammatory mediators and stroke:new opportunities for novel therapeutics.J Cereb Blood Flow Metab,1999,9(8):819–34.
44. Clark WM. Cytokines and reperfusion injury.Neurology,1997, 49 (suppl 4): S10–S14.
45. Kuroda S, Siesjo BK.Reperfusion damage following focal ischemia: pathophysiology and therapeutic windows.Clin Neurosci,1997,4(4):199–212.
46. Zhang RL,Chopp M,Chen H,et al.Temporal profile of ischemic tissue damage, neutrophil response,and vascular plugging following permanent and transient (2H) middle cerebral artery occlusion in the rat.J Neurol Sci,1994,125(1):3–10.
47. van Lookeren C,Thomas GR,Thibodeaux H,et al.Secondary reduction in the apparent diffusion coefficient of water,increase in cerebral blood volume,and delayed neuronal death after middle cerebral artery occlusion and early reperfusion in the rat.J Cereb Blood Flow Metab,1999,19(12):1354–64.
48. Zhang RL,Zhang ZG,Chopp M,et al.Thrombolysis with tissue plasminogen activator alters adhesion molecule expression in the ischemic rat brain.Stroke, 1999,30(3):624–9.
49. Zhang RL,Zhang ZG,Chopp M.Increased therapeutic efficacy with rt-PA and anti-CD18 antibody treatment of stroke in the rat.Neurology,1999, 52(2):273–9.
50. Kidwell CS,Saver JL,Mattiello J,et al.Thrombolytic reversal of acute human cerebral ischemic injury shown by diffusion/perfusion magnetic resonance imaging.Ann Neurol,2000,47(4):462–9.
51. Price CJ,Menon DK,Peters AM,et al.Cerebral Neutrophil Recruitment, Histology, and Outcome in Acute Ischemic Stroke.Stroke,2004,35(7):1659-64.
52. Okada Y,Copeland BR,Mori E,et al.P-selectin and intercellular adhesion molecule-1 expression after focal brain ischemia and reperfusion.Stroke, 1994,25(1):202–11.
53. Jander S,Kraemer M,Schroeter M,et al.Lymphocytic infiltration and expression of intercellular adhesion molecule-1 in photochemically induced ischemia of the rat cortex.J Cereb Blood Flow Metab,1995,15(1):42–51.
54. Zhang RL,Chopp M,Zaloga C,et al.The temporal profiles of ICAM-1 protein and mRNA expression after transient MCA occlusion in the rat.Brain Res,1995, 682(1-2):182–8.
55. Wang X,Yue TL,Barone FC,et al.Demonstration of increased endothelial-leukocyte adhesion molecule-1 mRNA expression in rat ischemic cortex.Stroke, 1995,26(9):1665–8.
56. Haring HP,Berg EL,Tsurushita N,et al.E-selectin appears in nonischemic tissue during experimental focal cerebral ischemia.Stroke,1996,27(8):1386–91.
57. Zhang RL,Chopp M,Zhang ZG,et al.E-selectin in focal cerebral ischemia and reperfusion in the rat.J Cereb Blood Flow Metab,1996,16(6):1126–36.
58. Huang J,Choudhri TF,Winfree CJ,et al.Postischemic cerebrovascular E-selectin expression mediates tissue injury in murine stroke.Stroke,2000,31(12): 3047–53.
59. Zhang R,Chopp M,Zhang Z,et al.The expression of P- and E-selectins in three models of middle cerebral artery occlusion.Brain Res,1998, 785(2):207–14.
60. Suzuki H,Abe K,Tojo S,et al.Expressions of P-selectin- and HSP72-like immunoreactivities in rat brain after transient middle cerebral artery occlusion.Brain Res,1997,759(2):321–9.
61. Suzuki H,Abe K,Tojo S,et al.A change of P-selectin immunoreactivity in rat brain after transient and permanent middle cerebral artery occlusion.Neurol Res,1998,20(5):463–9.
62. Hess DC,Zhao W,Carroll J,et al.Increased expression of ICAM-1 during reoxygenation in brain endothelial cells.Stroke,1994,25(7):1463–7.
63. Stanimirovic DB,Wong J,Shapiro A,et al.Increase in surface expression of ICAM-1,VCAM-1 and E-selectin in human cerebromicrovascular endothelial cells subjected to ischemia-like insults.Acta Neurochir Suppl (Wien),1997,70:12–6.
64. Howard EF,Chen Q,Cheng C,et al.NF-kappa B is activated and ICAM-1 gene expression is upregulated during reoxygenation of human brain endothelial cells.Neurosci Lett,1998,248(3):199–203.
65. Soriano SG,Coxon A,Wang YF,et al.Mice deficient in Mac-1 (CD11b/CD18) are less susceptible to cerebral ischemia/reperfusion injury.Stroke,1999,30(1):134–9.
66. Kitagawa K,Matsumoto M,Mabuchi T,et al.Deficiency of intercellular adhesion molecule-1 attenuates microcirculatory disturbance and infarction size in focal cerebral ischemia.J Cereb Blood Flow Metab,1998,18(12):1336–45.
67. Connolly ES Jr,Winfree CJ,Springer TA,et al.Cerebral protection in homozygous null ICAM-1 mice after middle cerebral artery occlusion: role of neutrophil adhesion in the pathogenesis of stroke.J Clin Invest,1996,97(1):209–16.
68. Suzuki H,Abe K,Tojo SJ,et al.Reduction of ischemic brain injury by anti- P-selectin monoclonal antibody after permanent middle cerebral artery occlusion in rat.Neurol Res,1999,21(3):269-76.
69. Zhang ZG, Chopp M, Tang WX, et al.Postischemic treatment (2-4 h) with anti-CD11b and anti-CD18 monoclonal antibodies are neuroprotective after transient (2 h) focal cerebral ischemia in the rat.Brain Res,1995,698(1-2):79-85.
70. Zhang RL,Chopp M, Li Y,et al.Anti-ICAM-1 antibody reduces ischemic cell damage after transient middle cerebral artery occlusion in the rat.Neurology, 1994,44(9):1747-51.
71. Chopp M, Zhang RL,Chen H,et al.Postischemic administration of an anti-Mac-1 antibody reduces ischemic cell damage after transient middle cerebral artery occlusion in rats.Stroke,1994,25(4):869-75.
72. Clark WM,Madden KP,Rothlein R,et al.Reduction of central nervous system ischemic injury by monoclonal antibody to intercellular adhesion molecule.J Neurosurg,1991,75(4):623–27.
73. Matsuo Y,Onodera H,Shiga Y,et al.Role of cell adhesion molecules in brain injury after transient middle cerebral artery occlusion in the rat.Brain Res,1994,656(2):344–52.
74. Bowes MP, Zivin JA, Rothlein R.Monoclonal antibody to the ICAM-1 adhesion site reduces neurological damage in a rabbit cerebral embolism stroke model.Exp Neurol,1993,119(2):215–9.
75. Chen H,Chopp M,Zhang RL,et al.Anti-CD11b monoclonal antibody reduces ischemic cell damage after transient focal cerebral ischemia in rat.Ann Neurol,1994, 35(4):458–63.
76. Chopp M,Zhang RL,Jiang N.The role of adhesion molecules in reducing cerebralischemic cell damage.Adv Neurol,1996,71: 315–26.
77. Zhang RL,Chopp M,Jiang N,et al.Anti-intercellular adhesion molecule-1 antibody reduces ischemic cell damage after transient but not permanent middle cerebral artery occlusion in the Wistar rat.Stroke,1995,26(8):1438–42.
78. Chopp M,Li Y,Jiang N,et al.Antibodies against adhesion molecules reduce apoptosis after transient middle cerebral artery occlusion in rat brain.J Cereb Blood Flow Metab,1996,16(4):578–84.
79. Morikawa E,Zhang SM,Seko Y,et al.Treatment of focal cerebral ischemia with synthetic oligopeptide corresponding to lectin domain of selectin.Stroke, 1996,27(5):951–5.
80. Goussev AV,Zhang Z,Anderson DC,et al.P-selectin antibody reduces hemorrhage and infarct volume resulting from MCA occlusion in the rat.J Neurol Sci,1998, 161(1):16-22.
81. Relton JK,Sloan KE,Frew EM,et al.Inhibition of 4 integrin protects against transient focal cerebral ischemia in normotensive and hypertensive rats.Stroke, 2001,32(1):199–205.
82. Becker K,Kindrick D,Relton J,et al.Antibody to the 4 integrin decreases infarct size in transient focal cerebral ischemia in rats.Stroke,2001,32(1): 206–11.
83. Bowes MP,Rothlein R,Fagan SC,et al.Monoclonal antibodies preventing leukocyte activation reduce experimental neurologic injury and enhance efficacy of thrombolytic therapy.Neurology,1995,45(4):815–9.
84. Bednar MM,Gross CE,Russell SR,et al.Humanized anti-L-selectin monoclonal antibody DREG200 therapy in acute thromboembolic stroke.Neurol Res,1998, 20(5):403–8.
85. Justicia C,Martin A,Rojas S,et al.Anti-VCAM-1 antibodies did not protect against ischemic damage either in rats or in mice.J Cereb Blood Flow Metab, 2006,26(3):421-432.
86. Enlimomab Acute Stroke Trial Investigators.Use of anti-ICAM-1 therapy in ischemic stroke: results of the Enlimomab Acute Stroke Trial.Neurology,2001, 57(8):1428–34.
87. Kanemoto Y,Nakase H,Akita N,et al.Effects of anti-intercellular adhesion molecule-1 antibody on reperfusion injury induced by late reperfusion in the rat middle cerebral artery occlusion model.Neurosurgery,2002,51(4):1034-41.
88. Mocco J,Choudhri T,Huang J,et al.HuEP5C7 as a humanized monoclonal anti-E/ P-selectin neurovascular protective strategy in a blinded placebo-controlled trial of nonhuman primate stroke.Circ Res,2002,91(10):907-14.
89. Lehmberg J,Beck J,Baethmann A,et al.Effect of P-selectin inhibition on leukocyte-endothelium interaction and survival after global cerebral ischemia. J Neurol,2006,253(3):357-63.
90. Atkinson C,Zhu H,Qiao F,et al.Complement-dependent P-selectin expression and injury following ischemic stroke.J Immunol,2006,177(10):7266-74.
91. Vemuganti R,Dempsey RJ,Bowen KK,et al.Inhibition of intercellular adhesion molecule-1 protein expression by antisense oligonucleotides is neuroprotectiveafter transient middle cerebral artery occlusion in rat.Stroke,2004,35(1): 179-84.
92. Zhang L,Zhang ZG,Zhang R,et al.Adjuvant treatment with a glycoprotein IIb/IIIa receptor inhibitor increases the therapeutic window for low-dose tissue plasminogen activator administration in a rat model of embolic strok. Circulation,2003,107(22):2837-43.
93. Ding G, Jiang Q,Zhang L,et al.Analysis of combined treatment of embolic stroke in rat with r-tPA and a GPIIb/IIIa inhibitor.J Cereb Blood Flow Metab,2005, 25(1):87-97.
94. Zhang L,Zhang ZG,Zhang C,et al.Intravenous administration of a GPIIb/IIIa receptor antagonist extends the therapeutic window of intra-arterial tenecteplase-tissue plasminogen activator in a rat stroke model.Stroke, 2004,35(12):2890-5.
95. Qureshi AI,Suri MF,Ali Z,et al.Intraarterial reteplase and intravenous abciximab for treatment of acute ischemic stroke.A preliminary feasibility and safety study in a non-human primate model.Neuroradiology,2005,47(11):845-54.
96. Moriguchi A, Mihara K,Aoki T,et al.Restoration of middle cerebral artery thrombosis by novel glycoprotein IIb/IIIa antagonist FK419 in guinea pig.Eur J Pharmacol,2004,498(1-3):179-88.
97. Maeda M,Moriguchi A,Mihara K,et al.FK419,a nonpeptide platelet glycoprotein IIb/IIIa antagonist,ameliorates brain infarction associated with thrombotic focal cerebral ischemia in monkeys:comparison with tissue plasminogen activator.J Cereb Blood Flow Metab,2005,25(1):108-18.
98. Lapchak PA,Araujo DM,Song D,et al. The nonpeptide glycoprotein IIb/IIIa platelet receptor antagonist SM-20302 reduces tissue plasminogen activator- induced intracerebral hemorrhage after thromboembolic stroke.Stroke,2002, 33(1):147-52.
99. Hu H,Zhang W,Li N.Glycoprotein IIb/IIIa inhibition attenuates platelet- activating factor-induced platelet activation by reducing protein kinase C activity.J Thromb Haemost,2003,1(8):1805-12.
100.Ritter LS,Stempel KM,Coull BM,et al.Leukocyte-platelet aggregates in rat peripheral blood after ischemic stroke and reperfusion.Biol Res Nurs,2005,6(4):281-8.
101. Zhang L,Zhang ZG,Zhang RL,et al.Effects of a selective CD11b/CD18 antagonist and recombinant human tissue plasminogen activator treatment alone and in combination in a rat embolic model of stroke.Stroke,2003,34(7):1790-5.
102. Carloni S,Mazzoni E,Cimino M,et al.Simvastatin reduces caspase-3 activation and inflammatory markers induced by hypoxia-ischemia in the newborn rat.Neurobiol Dis,2006,21(1):119-26.
103.Miao H,Jiang L,Huang L.Effects of simvastatin on the expression of intercellular adhesion molecule-1 mRNA in neonatal brain with hypoxic-ischemic damage.J Nanosci Nanotechnol,2005,5(8):1261-5.
104.Zhang L,Zhang ZG,Ding GL,et al.Multitargeted effects of statin-enhanced thrombolytic therapy for stroke with recombinant human tissue-type plasminogenactivator in the rat.Circulation,2005,112(22):3486-94.
105. Furuichi Y,Noto T,Li JY,et al.Multiple modes of action of tacrolimus (FK506) for neuroprotective action on ischemic damage after transient focal cerebral ischemia in rats.Brain Res,2004,1014(1-2):120-30.
106. Noto T,Furuichi Y,Ishiye M,et al.Tacrolimus (FK506) Limits Accumulation of Granulocytes and Platelets and Protects against Brain Damage after Transient Focal Cerebral Ischemia in Rat.Biol Pharm Bull,2007,30(2):313-7.
107. Khan M,Jatana M,Elango C,et al.Cerebrovascular protection by various nitric oxide donors in rats after experimental stroke.Nitric Oxide,2006,15(2):114-24.
108. Williams AJ, Dave JR,Tortella FC.Neuroprotection with the proteasome inhibitor MLN519 in focal ischemic brain injury:relation to nuclear factor kappaB (NF-kappaB),inflammatory gene expression, and leukocyte infiltration. Neurochem Int,2006,49(2):106-12.
109.He W,Xu XJ.Attenuation of brain inflammatory response after focal cerebral ischemia/reperfusion with Xuesaitong injection in rats.Chin J Integr Med,2006,12(3):203-6.
110. Cheng Y,Zhang HT,Sun L,et al.Involvement of cell adhesion molecules in polydatin protection of brain tissues from ischemia-reperfusion injury.Brain Res,2006, 1110(1):193-200.
111. Hu XM,Zhang Y,Zeng FD.Effects of sodium beta-aescin on expression of adhesion molecules and migration of neutrophils after middle cerebral artery occlusion in rats.Acta Pharmacol Sin,2004,25(7):869-75.
112.Wang YH,Wang WY,Chang CC,et al.Taxifolin ameliorates cerebral ischemia- reperfusion injury in rats through its anti-oxidative effect and modulation of NF-kappa B activation.J Biomed Sci,2006,13(1):127-41.
113.Littleton-Kearney MT,Gaines JM,Callahan KP,et al.Effects of estrogen on platelet reactivity after transient forebrain ischemia in rats.Biol Res Nurs, 2005,7(2):135-45.
114. Bowen KK,Naylor M,Vemuganti R.Prevention of inflammation is a mechanism of preconditioning-induced neuroprotection against focal cerebral ischemia. Neurochem Int,2006,49(2):127-35.
115. Duan H,Cheng L,Sun X,et al.LFA-1 and VLA-4 involved in human high proliferative potential-endothelial progenitor cells homing to ischemic tissue.Thromb Haemost,2006,96(6):807-15.
116. Zhang J,Rui YC,Yang PY,et al.C-reactive protein induced expression of adhesion molecules in cultured cerebral microvascular endothelial cells.Life Sci,2006, 78(26):2983-8.
117. Rassoul F,Salvetter J,Reissig D,et al.The influence of garlic (Allium sativum) extract on interleukin 1alpha-induced expression of endothelial intercellular adhesion molecule-1 and vascular cell adhesion molecule-1.Phytomedicine, 2006,13(4):230-5.
118. Handrigan MT,Burns AR,Donnachie EM,et al.Hydroxyethyl starch inhibits neutrophil adhesion and transendothelial migration.Shock,2005,24(5):434-9.
119.Wang GJ,Deng HY,Maier CM,et al.Mild hypothermia reduces ICAM-1 expression, neutrophil infiltration and microglia/monocyte accumulation following experimental stroke.Neuroscience,2002,114(4):1081–90.
120.Arumugam TV,Salter JW,Chidlow JH,et al.Contributions of LFA-1 and Mac-1 to brain injury and microvascular dysfunction induced by transient middle cerebral artery occlusion.Am J Physiol Heart Circ Physiol,2004,287(6):H2555-60.
121.Chen Y,Ruetzler C,Pandipati S,et al.Mucosal tolerance to E-selectin provides cell-mediated protection against ischemic brain injury.Proc Natl Acad Sci U S A.2003,100(25):15107-12.
122.Kim JS,Chopp M,Chen H,et al.Adhesive glycoproteins CD11a and CD18 are upregulated in the leukocytes from patients with ischemic stroke and transient ischemic attacks.J Neurol Sci,1995,128(1):45–50.
123.Fiszer U,Korczak-Kowalska G,Palasik W,et al.Increased expression of adhesion molecule CD18 (LFA-1beta) on the leukocytes of peripheral blood in patients with acute ischemic stroke.Acta Neurol Scand,1998, 97(4):221–224.
124.夏斌,邵福源,赵忠新,等.急性缺血性脑血管病患者血清可溶性黏附分子的变化.上海医学,2002,25(5):308-9.
125.夏斌,张玲珍,邵福源,等.缺血性脑血管意外患者白细胞 CD11b 和 CD18 的表达.中华内科杂志,1999,38(9):637-8.
126.夏斌,张玲珍,邵福源,等.缺血性卒中患者白细胞粘附分子的表达.中国神经精神疾病杂志,2000,26(5):310-1.
127.夏斌,张玲珍,邵福源,等.急性缺血性脑卒中患者血小板膜糖蛋白的表达.中华老年医学杂志,1999,18(6):337-9.
128.夏斌,张玲珍,邵福源,等.缺血性卒中患者血小板-白细胞粘附性的变化.中华老年医学杂志,2000,19(3):223-4.
129.Sanchez-Moreno C,Dashe JF,Scott T,et al.Decreased levels of plasma vitamin C and increased concentrations of inflammatory and oxidative stress markers after stroke.Stroke,2004,35(1):163-8.
130. Simundic AM,Basic V,Topic E,et al.Soluble adhesion molecules in acute ischemic stroke.Clin Invest Med,2004,27(2):86-92.
131. Licata G,Tuttolomondo A,Corrao S,et al.Immunoinflammatory activation during the acute phase of lacunar and non-lacunar ischemic stroke:association with time of onset and diabetic state.Int J Immunopathol Pharmacol,2006,19(3):639-46.
132. Castellanos M, Castillo J, Garcia MM,et al.Inflammation-mediated damage in progressing lacunar infarctions:a potential therapeutic target.Stroke,2002, 33(4):982-7.
133. Wang JY,Zhou DH,Li J,et al.Association of soluble intercellular adhesion molecule 1 with neurological deterioration of ischemic stroke:The Chongqing Stroke Study.Cerebrovasc Dis,2006,21(1-2):67-73.
134.Wang J,Li J,Liu Q.Association between platelet activation and fibrinolysis in acute stroke patients.Neurosci Lett,2005,384(3):305-9.
135. Cherian P,Hankey GJ, Eikelboom JW,et al.Endothelial and platelet activation in acute ischemic stroke and its etiological subtypes.Stroke,2003,34(9):2132-7.
136.Kozuka K,Kohriyama T,Nomura E,et al.Endothelial markers and adhesion molecules in acute ischemic stroke--sequential change and differences in stroke subtype. Atherosclerosis.2002,161(1):161-8.
137. Brondani R,Rieder CR,Valente D,et al.Levels of vascular cell adhesion molecule-1 and endothelin-1 in ischemic stroke: A longitudinal prospective study.Clin Biochem,2007,40(3-4):282-4.
138.Rodriguez-Yanez M,Castellanos M,Blanco M,et al.New-onset hypertension and inflammatory response/poor outcome in acute ischemic stroke.Neurology,2006, 67(11):1973-8.
139.Nadar SK,Lip GY,Blann AD.Platelet morphology, soluble P selectin and platelet P-selectin in acute ischaemic stroke. The West Birmingham Stroke Project.Thromb Haemost,2004,92(6):1342-8.
140.Htun P, Fateh-Moghadam S,Tomandl B,et al.Course of platelet activation and platelet-leukocyte interaction in cerebrovascular ischemia.Stroke,2006,37(9): 2283-7.
141.Anzej S,Bozic M,Antovic A, et al.Evidence of hypercoagulability and inflammation in young patients long after acute cerebral ischaemia.Thromb Res. 2006,[Epub ahead of print]
142.McCabe DJ,Harrison P,Mackie IJ,et al.Platelet degranulation and monocyte-platelet complex formation are increased in the acute and convalescent phases after ischaemic stroke or transient ischaemic attack.Br J Haematol, 2004,125(6):777-87.
143.Marquardt L, Ruf A, Mansmann U,et al. Course of Platelet Activation Markers After Ischemic Stroke.Stroke,2002,33(11):2570-4.
144. Wang J,Li J,Liu Q.Association between platelet activation and fibrinolysis in acute stroke patients.Neurosci Lett,2005,384(3):305-9.
145. Li N, Hu H, Hjemdahl P.Aspirin treatment does not attenuate platelet or leukocyte activation as monitored by whole blood flow cytometry.Thromb Res.2003, 111(3):165-70.
146. Serebruany VL,Malinin AI,Oshrine BR,et al.Lack of uniform platelet activation in patients after ischemic stroke and choice of antiplatelet therapy.Thromb Res, 2004,113(3-4):197-204.
147. Serebruany VL,Malinin AI,Ziai W,et al.Effects of clopidogrel and aspirin in combination versus aspirin alone on platelet activation and major receptor expression in patients after recent ischemic stroke:for the Plavix Use for Treatment of Stroke (PLUTO-Stroke) trial.Stroke,2005,36(10):2289-92.
148. Yip HK,Chen SS,Liu JS,et al.Serial changes in platelet activation in patients after ischemic stroke:role of pharmacodynamic modulation.Stroke,2004, 35(7):1683-7.
149. Wallaschofski H, Lohmann T, Hild E,et al.Enhanced platelet activation by prolactin in patients with ischemic stroke.Thromb Haemost,2006,96(1):38-44.
150.Tomiyasu H,Ishikawa K,Yamamoto M,et al.Effect of anticholesterol therapy on soluble ICAM-1 in chronic stroke patients with hyperlipidemia.Tokai J Exp ClinMed,2005,30(1):63-9.
151.Cha JK,Jeong MH,Kim JW.Statin reduces the platelet P-selectin expression in atherosclerotic ischemic stroke.J Thromb Thrombolysis,2004,18(1):39-42.
152. Zeller JA,Lenz A,Eschenfelder CC,et al.Platelet-leukocyte interaction and platelet activation in acute stroke with and without preceding infection. Arterioscler Thromb Vasc Biol,2005,25(7):1519-23.
153.Sobel RA,Mitchell ME,Fondren G.Intercellular adhesion molecule-1 (ICAM-1) in cellular immune reactions in the human central nervous system.Am J Pathol,1990,136(6):1309–16.
154.Krupinski J,Kaluza J,Kumar P,et al.Role of angiogenesis in patients with cerebral ischemic stroke.Stroke,1994,25(9):1794–8.
155.Lindsberg PJ,Carpen O,Paetau A,et al.Endothelial ICAM-1 expression associated with inflammatory cell response in human ischemic stroke. Circulation,1996, 94(5):939–5.
156. Padma V, Fisher M, Moonis M.et al.Thrombolytic therapy for acute ischemic stroke: 3 h and beyond.Expert Rev Neurother,2005,5(2):223-33.
157. Kaneider NC,Leger AJ,Kuliopulos A.Therapeutic targeting of molecules involved in leukocyte-endothelial cell interactions.FEBS J, 2006,273(19): 4416-24.
158.DeGraba TJ.The role of inflammation after acute stroke:utility of pursuing anti-adhesion molecule therapy.Neurology,1998,51(suppl 3):S62–8.
159.Schneider D,Berrouschot J,Brandt T,et al.Safety, pharmacokinetics and biological activity of enlimomab (anti-ICAM-1 antibody):an open-label,dose escalation study in patients hospitalized for acute stroke.Eur Neurol,1998, 40(2):78–83.
160.Vuorte J,Lindsberg PJ,Kaste M,et al.Anti-ICAM-1 monoclonal antibody R6.5 (enlimomab) promotes activation of neutrophils in whole blood.J Immunol,1999, 162(4):2353–7.
161.Furuya K,Takeda H,Azhar S,et al.Examination of several potential mechanisms for the negative outcome in a clinical stroke trial of enlimomab,a murine anti-human intercellular adhesion molecule-1 antibody: a bedside-to-bench study.Stroke, 2001,32(11):2665–74.
162.del Zoppo GJ,Hallenbeck JM.Advances in the vascular pathophysiology of ischemic stroke.Thromb Res,2000,98(3): 73–81.
163.Zanette EM,Roberti C,Mancini G,et al.Spontaneous middle cerebral artery reperfusion in ischemic stroke:a follow-up study with transcranial Doppler. Stroke,1995,26(3):430–3.
164.Lu M,Krams M,Zhang L,et al.Assessing combination treatments in acute stroke: preclinical experiences.Behav Brain Res,2005,162(2):165-72.
165. Mileski WJ,Burkhart D,Hunt JL,et al.Clinical effects of inhibiting leukocyte adhesion with monoclonal antibody to intercellular adhesion molecule-1 (enlimomab) in the treatment of partial-thickness burn injury.J Trauma, 2003,54(5):950-8.
166. Salmela K,Wramner L,Ekberg H,et al.A randomized multicenter trial of theanti-ICAM-1 monoclonal antibody (enlimomab) for the prevention of acute rejection and delayed onset of graft function in cadaveric renal transplantation: a report of the European Anti-ICAM-1 Renal Transplant Study Group. Transplantation,1999,67(5):729-36.
167.Jiang N,Chopp M,Chahwala S.Neutrophil inhibitory factor treatment of focal cerebral ischemia in the rat.Brain Res,1998,788(1-2):25–34.
168.Lees KR,Diener HC,Asplund K,et al;UK-279,276-301 Study Investigators. UK-279,276,a neutrophil inhibitory glycoprotein,in acute stroke:tolerability and pharmacokinetics.Stroke,2003,34(7):1704–9.
169.Krams M, Lees KR, Hacke W,et al. ASTIN Study Investigators. Acute Stroke Therapy by Inhibition of Neutrophils (ASTIN):an adaptive dose-response study of UK-279,276 in acute ischemic stroke.Stroke,2003,34(11):2543-8.
170.Sughrue ME, Connolly ES Jr.Effectively Bridging the Preclinical/Clinical Gap: The Results of the ASTIN Trial.Stroke,2004,35(4):e81-2.
171.Adams HP, Adams RJ,Brott T,del Zoppo GJ,et al;Stroke Council of the American Stroke Association.Guidelines for the early management of patients with ischemic stroke.A scientific statement from the stroke council of the Am Stroke Association.Stroke,2003,34(4):1056–83.
172.Molina CA,Saver JL.Extending reperfusion therapy for acute ischemic stroke:emerging pharmacological,mechanical,and imaging strategies.Stroke, 2005,36(10):2311-20.
173.Schwarz M, Nordt T, Bode C, Peter K.The GP IIb/IIIa inhibitor abciximab (c7E3) inhibits the binding of various ligands to the leukocyte integrin Mac-1 (CD11b/CD18).Thromb Res,2002,107(3-4):121–8.
174.Fintel DJ.From bench to bedside:GP IIb-IIIa inhibitors.Neurology,2001,57(5 Suppl 2):S12–9.
175.The Abciximab in Ischemic Stroke Investigators.Abciximab in acute ischemic stroke: a randomized, double-blind, placebo-controlled, dose-escalation study. Stroke,2000,31(3):601-9.
176.Abciximab Emergent Stroke Treatment Trial (AbESTT) Investigators.Emergency administration of abciximab for treatment of patients with acute ischemic stroke:results of a randomized phase 2 trial.Stroke,2005,36(4):880-90.
177. Ciccone A,Abraha I,Santilli I. Glycoprotein IIb-IIIa inhibitors for acute ischaemic stroke.Cochrane Database Syst Rev,2006, 18;(4):CD005208.
178. Mitsias PD,Lu M,Silver B,et al.MRI-guided,open trial of abciximab for ischemic stroke within a 3- to 24-hour window.Neurology,2005,65(4):612-5.
179.Heo JH, lee KY, Kim SH,et al.Immediate reocclusion following a successful thrombolysis in acute stroke:a pilot study.Neurology,2003, 60(10),1684–6.
180.Hofmann R,Kerschner K,Steinwender C,et al.Abciximab bolus injection does not reduce cerebral ischemic complications of elective carotid artery stenting:a randomized study.Stroke,2002,33(3):725–7.
181.Wholey MH, Eles G,Toursakissian B,et al.Evaluation of glycoprotein IIb/IIIa inhibitors in carotid angioplasty and stenting.J Endovasc Ther,2003,10(1): 33–41.
182.Bush RL,Lin PH, Bianco CC,et al.Carotid artery stenting in a community setting: experience outside of a clinical trial.Ann Vasc Surg,2003,17(6):629–34.
183.Lee DH,Jo KD,Kim HG,et al.Local intra-arterial urokinase thrombolysis of acute ischemic stroke with or without intravenous abciximab:a pilot study.J Vasc Interv Radiol,2002,13(8):769–73.
184.Morris DC, Silver B, Mitsias P,et al.Treatment of acute stroke with recombinant tissue plasminogen activator and abciximab.Acad Emerg Med,2003,10(12): 1396–1399.
185. Kopp CW,Steiner S,Nasel C,et al.Abciximab reduces monocyte tissue factor in carotid angioplasty and stenting.Stroke,2003,34(11):2560–7.
186. Qureshi AI,Harris-Lane P,Kirmani JF,et al.Intra-arterial reteplase and intravenous abciximab in patients with acute ischemic stroke:an open-label, dose-ranging,phase I study.Neurosurgery,2006,59(4):789-96.
187. Eckert B,Koch C,Thomalla G,et al.Aggressive therapy with intravenous abciximab and intra-arterial rtPA and additional PTA/stenting improves clinical outcome in acute vertebrobasilar occlusion:combined local fibrinolysis and intravenous abciximab in acute vertebrobasilar stroke treatment (FAST):results of a multicenter study.Stroke,2005,36(6):1160-5.
188.Abou-Chebl A,Bajzer CT,Krieger DW,et al.Multimodal therapy for the treatment of severe ischemic stroke combining GPIIb/IIIa antagonists and angioplasty after failure of thrombolysis.Stroke,2005,36(10):2286-8.
189.Gupta R,Vora NA,Horowitz MB,et al.Multimodal reperfusion therapy for acute ischemic stroke:factors predicting vessel recanalization.Stroke,2006,37(4): 986-90.
190.Velat GJ, Burry MV, Eskioglu E,et al.The use of abciximab in the treatment of acute cerebral thromboembolic events during neuroendovascular procedures.Surg Neurol,2006,65(4):352-8.
191.Junghans U,Seitz RJ,Aulich A,et al.Bleeding risk of tirofiban,a nonpeptide GPIIb/IIIa platelet receptor antagonist in progressive stroke: an open pilot study.Cerebrovasc Dis,2001,12(4):308–12.
192.Junghans U,Seitz RJ,Ritzl A,et al.Ischemic brain tissue salvaged from infarction by the GP IIb/IIIa platelet antagonist tirofiban.Neurology,2002,58(3):474–6.
193.Seitz RJ,Meisel S,Moll M,et al.The effect of combined thrombolysis with rtPA and tirofiban on ischemic brain lesions.Neurology,2004,62(11):2110–2.
194.Straub S,Junghans U,Jovanovic V,et al.Systemic thrombolysis with recombinant tissue plasminogen activator and tirofiban in acute middle cerebral artery occlusion.Stroke,2004,35(3):705–9.
195. Seitz RJ,Hamzavi M,Junghans U,et al.Thrombolysis with recombinant tissue plasminogen activator and tirofiban in stroke:preliminary observations. Stroke, 2003,34(8):1932-5.
196.Bukow SC,Daffertshofer M,Hennerici MG.Tirofiban for the treatment of ischaemic stroke.Expert Opin Pharmacother,2006,7(1):73-9.
197. Mangiafico S,Cellerini M,Nencini P,et al.Intravenous glycoprotein IIb/IIIainhibitor (tirofiban) followed by intra-arterial urokinase and mechanical thrombolysis in stroke.AJNR Am J Neuroradiol,2005,26(10):2595-601.
198. Mangiafico S,Cellerini M,Nencini P,et al.Intravenous tirofiban with intra-arterial urokinase and mechanical thrombolysis in stroke: preliminary experience in 11 cases.Stroke,2005,36(10):2154-8.
199.Junghans U,Siebler M.Cerebral microembolism is blocked by tirofiban,a selective nonpeptide platelet glycoprotein IIb/IIIa receptor antagonist.Circulation, 2003,107(21):2717-21.
200. Topol EJ,Easton D,Harrington RA,et al.Randomized,double-blind,placebo- controlled,international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease.Circulation,2003,108(4):399-406.
201. Wang WY,Wu YC,Wu CC.Prevention of platelet glycoprotein IIb/IIIa activation by 3,4-methylenedioxy-beta-nitrostyrene,a novel tyrosine kinase inhibitor.Mol Pharmacol,2006,70(4):1380-9.
202. Tanne D,Haim M,Boyko V,et al.Soluble intercellular adhesion molecule-1 and risk of future ischemic stroke:a nested case-control study from the Bezafibrate Infarction Prevention (BIP) study cohort.Stroke,2002,33(9):2182-6.
203.Kawamura T,Umemura T,Kanai A, et al.Soluble adhesion molecules and C-reactive protein in the progression of silent cerebral infarction in patients with type 2 diabetes mellitus.Metabolism,2006,55(4):461-6.
204.Jenny NS, Arnold AM, Kuller LH, et al.Soluble intracellular adhesion molecule-1 is associated with cardiovascular disease risk and mortality in older adults. J Thromb Haemost.2006,4(1):107-13.
205.夏斌,李莉,赵忠新,等.可溶性 ICAM-1 与脑梗死复发的前瞻性研究中华医学杂志.2005,85(18):1279-81.
206.Ehrensperger E,Minuk J,Durcan L,et al.Predictive value of soluble intercellular adhesion molecule-1 for risk of ischemic events in individuals with cerebrovascular disease.Cerebrovasc Dis,2005,20(6):456-62.
207.Campbell DJ,Woodward M,Chalmers JP,et al.Soluble Vascular Cell Adhesion Molecule 1 and N-terminal Pro–B-Type Natriuretic Peptide in Predicting Ischemic Stroke in Patients With Cerebrovascular Disease.Arch Neurol,2006, 63(1):60-65.
208.Heeringa J,Conway DS,van der Kuip DA,et al.A longitudinal population-based study of prothrombotic factors in elderly subjects with atrial fibrillation:the Rotterdam Study 1990-1999.J Thromb Haemost,2006,4(9):1944-9.
209.Volcik KA, Ballantyne CM, Coresh J,et al.P-selectin Thr715Pro polymorphism predicts P-selectin levels but not risk of incident coronary heart disease or ischemic stroke in a cohort of 14595 participants: the Atherosclerosis Risk in Communities Study.Atherosclerosis,2006,186(1):74-79.
210. Ferrari J,Rieger S,Endler G,et al.The Thr715Pro polymorphism of the P-selectin gene is not associated with ischemic stroke risk.Stroke,2007,38(2):395-7.
211. Pola R,Flex A,Gaetani E,et al.Synergistic Effect of -174 G/C Polymorphism of the Interleukin-6 Gene Promoter and 469 E/K Polymorphism of the IntercellularAdhesion Molecule-1 Gene in Italian Patients With History of Ischemic Stroke. Stroke,2003,34(4):881-5.
212.Bertges DJ,Muluk V,Whittle J,et al.Relevance of carotid stenosis progression as a predictor of ischemic neurological outcomes.Arch Intern Med,2003,163(19):2285–9.
213.Libby P,Ridker P,Maseri A.Inflammation and atherosclerosis.Circulation.2002, 105(9):1135–43.
214. Schillinger M,Exner M,Mlekusch W,et al,Inflammation and Carotid Artery—Risk for Atherosclerosis Study (ICARAS).Circulation,2005,111(17):2203-9.
215. Quehenberger O.Thematic review series:the immune system and atherogenesis. Molecular mechanisms regulating monocyte recruitment in atherosclerosis.J Lipid Res,2005,46(8):1582-90.
216.Hashimoto H,Kitagawa K,Kuwabara K,et al.Circulating adhesion molecules are correlated with ultrasonic assessment of carotid plaques.Clin Sci (Lond),2003, 104(5):521-7.
217.Amar J,Fauvel J,Drouet L,et al.Interleukin 6 is associated with subclinical atherosclerosis:a link with soluble intercellular adhesion molecule 1.J Hypertens,2006,24(6):1083-8.
218.Kondo K,Kitagawa K,Nagai Y,et al.Associations of soluble intercellular adhesion molecule-1 with carotid atherosclerosis progression.Atherosclerosis,2005, 179(1):155-60.
219.Hulthe J,Wikstrand J,Mattsson-Hulten L,et al.Circulating ICAM-1 (intercellular cell-adhesion molecule 1) is associated with early stages of atherosclerosis development and with inflammatory cytokines in healthy 58-year-old men:the Atherosclerosis and Insulin Resistance (AIR) study.Clin Sci (Lond),2002, 103(2):123-9.
220.Larsson PT,Hallerstam S,Rosfors S,et al.Circulating markers of inflammation are related to carotid artery atherosclerosis.Int Angiol,2005,24(1):43-51.
221. Chironi G,Dosquet C,Del-Pino M,et al.Relationship of circulating biomarkers of inflammation and hemostasis with preclinical atherosclerotic burden in nonsmoking hypercholesterolemic men.Am J Hypertens,2006,19(10):1025-31.
222.Koyama H,Maeno T,Fukumoto S,et al.Platelet P-selectin expression is associated with atherosclerotic wall thickness in carotid artery in humans.Circulation, 2003,108(5):524-9.
223.Yip HK,Lu CH,Yang CH,et al.Levels and value of platelet activity in patients with severe internal carotid artery stenosis. Neurology,2006,66(6):804-8.
224. McCabe DJ,Harrison P,Mackie IJ, et al.Increased platelet count and leucocyte-platelet complex formation in acute symptomatic compared with asymptomatic severe carotid stenosis.J Neurol Neurosurg Psychiatry,2005,76(9): 1249-54.
225.Shoji T,Koyama H,Fukumoto S,et al.Platelet-monocyte aggregates are independently associated with occurrence of carotid plaques in type 2 diabeticpatients.J Atheroscler Thromb,2005,12(6):344-52.
226.Testa A,Benedetto FA,Spoto B,et al.The E-selectin gene polymorphism and carotid atherosclerosis in end-stage renal disease.Nephrol Dial Transplant,2006, 21(7):1921-6.
227. Yang PY, Rui YC.Intercellular adhesion molecule-1 and vascular endothelial growth factor expression kinetics in macrophage-derived foam cells.Life Sci,2003,74(4):471-80.
228. Yang PY, Almofti MR, Lu L,et al.Reduction of atherosclerosis in cholesterol-fed rabbits and decrease of expressions of intracellular adhesion molecule-1 and vascular endothelial growth factor in foam cells by a water-soluble fraction of Polygonum multiflorum.J Pharmacol Sci,2005,99(3):294-300.
229. Yoshii T,Iwai M,Li Z,et al.Regression of atherosclerosis by amlodipine via anti-inflammatory and anti-oxidative stress actions.Hypertens Res,2006,29(6): 457-66.
230. Zhu S,Su G,Meng QH.Inhibitory effects of micronized fenofibrate on carotid atherosclerosis in patients with essential hypertension.Clin Chem,2006, 52(11):2036-42.
231.Sumino H,Ichikawa S,Kasama S,et al.Effect of transdermal hormone replacement therapy on carotid artery wall thickness and levels of vascular inflammatory markers in postmenopausal women.Hypertens Res,2005,28(7):579-84.
232. Nadar SK,Blann AD,Kamath S,et al.Platelet indexes in relation to target organ damage in high-risk hypertensive patients: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT).J Am Coll Cardiol,2004,44(2):415-22.
233.Glowinska B,Urban M,Peczynska J,et al.Soluble adhesion molecules (sICAM-1, sVCAM-1) and selectins (sE selectin, sP selectin, sL selectin) levels in children and adolescents with obesity,hypertension,and diabetes.Metabolism, 2005,54(8):1020-6.
234. Nadar S,Blann AD,Lip GY. Platelet morphology and plasma indices of platelet activation in essential hypertension:effects of amlodipine-based antihypertensive therapy.Ann Med,2004,6(7):552-7.
235.Sironi L,Gianazza E,Gelosa P,et al.Rosuvastatin,but not simvastatin,provides end-organ protection in stroke-prone rats by antiinflammatory effects. Arterioscler Thromb Vasc Biol,2005,25(3):598-603.
236.Hoogeveen RC,Ballantyne CM,Bang H,et al.Circulating oxidised low-density lipoprotein and intercellular adhesion molecule-1 and risk of type 2 diabetes mellitus:the Atherosclerosis Risk in Communities Study.Diabetologia,2007, 50(1):36-42.
237.Soedamah-Muthu SS,Chaturvedi N,Schalkwijk CG,et al.Soluble vascular cell adhesion molecule-1 and soluble E-selectin are associated with micro- and macrovascular complications in Type 1 diabetic patients.J Diabetes Complications,2006,20(3):188-95.
238.Hu H,Hjemdahl P,Li N.Effects of insulin on platelet and leukocyte activity inwhole blood.Thromb Res,2002,107(5):209-15.
239.Kent JW Jr,Comuzzie AG,Mahaney MC,et al.Intercellular adhesion molecule-1 concentration is genetically correlated with insulin resistance,obesity,and HDL concentration in Mexican Americans.Diabetes,2004,53(10):2691-5.
240. Yip HK,Wu CJ,Hang CL,et al.Levels and values of inflammatory markers in patients with angina pectoris.Int Heart J,2005,46(4):571-81.
241.Turhan H,Saydam GS,Erbay AR,et al.Increased plasma soluble adhesion molecules; ICAM-1, VCAM-1, and E-selectin levels in patients with slow coronary flow.Int J Cardiol,2006,108(2):224-30.
242. Fang L, Wei H, Mak KH, et al.Markers of low-grade inflammation and soluble cell adhesion molecules in Chinese patients with coronary artery disease.Can J Cardiol,2004,20(14):1433-8.
243.Skilton MR, Nakhla S,Sieveking DP,et al. Pathophysiological levels of the obesity related peptides resistin and ghrelin increase adhesion molecule expression on human vascular endothelial cells.Clin Exp Pharmacol Physiol,2005,32(10):839-44.
244.Sejda T,Jedliekova V,Svandova E,et al.The effect of fluvastatin on cICAM-1 as a biomarker of endothelial dysfunction in patients with dyslipidemia.Int Angiol,2006,25(4):414-7.
245.Zeller JA, Frahm K,Baron R,et al.Platelet-leukocyte interaction and platelet activation in migraine:a link to ischemic stroke?J Neurol Neurosurg Psychiatry,2004,75(7):984-7.
246.Mayberg MR.Cerebral vasospasm.Neurosurg Clin N Am,1998,9(3): 615–27.
247.Feigin VL,Rinkel GJ,Algra A,et al.Calcium antagonists in patients with aneurysmal subarachnoid hemorrhage:a systematic review.Neurology,1998,50(4): 876–83.
248.Thai QA,Oshiro EM,Tamargo RJ.Inhibition of experimental vasospasm in rats with the periadventitial administration of ibuprofen using controlled-release polymers.Stroke,1999,30(1):140–7.
249.Bavbek M,Polin R,Kwan AL,et al.Monoclonal antibodies against ICAM-1 and CD18 attenuate cerebral vasospasm after experimental subarachnoid hemorrhage in rabbits.Stroke,1998,29(9):1930–5.
250.Oshiro EM,Hoffman PA,Dietsch GN,et al.Inhibition of experimental vasospasm with anti-intercellular adhesion molecule-1 monoclonal antibody in rats.Stroke, 1997.28(10):2031–7.
251.Sills AKJ,Clatterbuck RE,Thompson RC,et al.Endothelial cell expression of intercellular adhesion molecule 1 in experimental posthemorrhagic vasospasm. Neurosurgery,1997,41(2):453–60.
252. Tanriverdi T,Kafadar AM,et al.Detection of soluble intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in both cerebrospinal fluid and serum of patients after aneurysmal subarachnoid hemorrhage.J Neurosurg, 2004,101(6):1030-6.
253.Mack WJ,Mocco J,Hoh DJ,et al.Outcome prediction with serum intercellular adhesion molecule-1 levels after aneurysmal subarachnoid hemorrhage.JNeurosurg,2002,96(1):71–5.
254.Mocco J,Mack WJ,Kim GH,et al. Rise in serum soluble intercellular adhesion molecule-1 levels with vasospasm following aneurysmal subarachnoid hemorrhage. J Neurosurg,2002,97(3):537-41
255. Rothoerl RD,Schebesch KM,Kubitza M,et al.ICAM-1 and VCAM-1 expression following aneurysmal subarachnoid hemorrhage and their possible role in the pathophysiology of subsequent ischemic deficits.Cerebrovasc Dis,2006,22(2-3): 143-9.
256.Frijns CJ,Fijnheer R,Algra A,et al.Early circulating levels of endothelial cell activation markers in aneurysmal subarachnoid haemorrhage:associations with cerebral ischaemic events and outcome. J Neurol Neurosurg Psychiatry,2006, 77(1):77-83.
257. Frijns CJ,Kasius KM,Algra A,et al.Endothelial cell activation markers and delayed cerebral ischaemia in patients with subarachnoid haemorrhage.J Neurol Neurosurg Psychiatry,2006,77(7):863-7.
258.Pradilla G,Wang PP,Legnani FG,et al.Prevention of vasospasm by anti-CD11/CD18 monoclonal antibody therapy following subarachnoid hemorrhage in rabbits.J Neurosurg,2004,101(1):88-92.
259. Lin CL,Dumont AS,Calisaneller T,et al.Monoclonal antibody against E selectin attenuates subarachnoid hemorrhage-induced cerebral vasospasm.Surg Neurol, 2005,64(3):201-5.
260.Lindsberg PJ,Roine RO,Tatlisumak T,et al.The future of stroke treatment.Neurol Clin,2000,18():495–510.
261.Nahrendorf M,Jaffer FA,Kelly KA,et al.Noninvasive vascular cell adhesion molecule-1 imaging identifies inflammatory activation of cells in atherosclerosis.Circulation,2006,114(14):1504-11.